var title_f31_21_32080="Axial CT of second branchial cleft cyst";
var content_f31_21_32080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F81496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F81496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Axial CT of second branchial cleft cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32080=[""].join("\n");
var outline_f31_21_32080=null;
var title_f31_21_32081="Adrenal glands in relation to the kidneys and great vessels";
var content_f31_21_32081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Adrenal glands in relation to the kidneys and great vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The adrenal glands are retroperitoneal and are located on the superior medial aspect of the upper pole of each kidney. This illustrates the frontal or intra-abdominal view of the kidneys and adrenal glands.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32081=[""].join("\n");
var outline_f31_21_32081=null;
var title_f31_21_32082="Extramedullary plasmacytoma";
var content_f31_21_32082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79555&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extramedullary plasmacytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large red-purple-appearing plasmacytoma on lower back in patient with relapsed multiple myeloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32082=[""].join("\n");
var outline_f31_21_32082=null;
var title_f31_21_32083="Chondro histology rare";
var content_f31_21_32083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Histology of rare chondrosarcoma subtypes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 175px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Histology of dedifferentiated chondrosarcoma with a sharp interface between conventional chondrosarcoma (left) and anaplastic sarcoma (right). B) Mesenchymal chondrosarcoma with undifferentiated small blue round cells (below) and cartilage differentiation (top). C) Clear cell chondrosarcoma demonstrating chondrocytes with abundant clear cytoplasm, cartilaginous matrix, and deposition of osteoid (hematoxylin and eosin staining, &sim;500X).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gelderblom H, Hogendoorn PCW, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13:320. Copyright &copy;2008 AlphaMed Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.TheOncologist.com\">",
"      file://www.TheOncologist.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32083=[""].join("\n");
var outline_f31_21_32083=null;
var title_f31_21_32084="Amphotericin B lipid complex: Patient drug information";
var content_f31_21_32084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amphotericin B lipid complex: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"     see \"Amphotericin B lipid complex: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/41/42646?source=see_link\">",
"     see \"Amphotericin B lipid complex: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Abelcet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abelcet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amphotericin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need extra potassium or magnesium. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. You may be given drugs before this shot to avoid these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy or pink-red urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11497 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32084=[""].join("\n");
var outline_f31_21_32084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134818\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134819\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026657\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026659\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026658\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026663\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026664\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026666\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026661\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026662\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026667\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026668\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=related_link\">",
"      Amphotericin B lipid complex: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/41/42646?source=related_link\">",
"      Amphotericin B lipid complex: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_21_32085="Stress test PI";
var content_f31_21_32085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Person having a stress test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows a person having a stress test. During a stress test, people either exercise (such as on a treadmill, shown here) or take medicine to make their heart pump faster. A test called an ECG (also called an electrocardiogram or EKG) is done during the stress test. For an ECG, patches (called \"electrodes\") are stuck to a person's chest. Wires run from the patches to the ECG machine to measure the electrical activity in the heart. People also have their blood pressure checked during a stress test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: NHLBI Diseases and Conditions Index. Stress testing: What to expect during stress testing. National Heart Lung and Blood Institute. Available at:",
"     <a href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/stress/stress_during.html\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/health/dci/Diseases/stress/stress_during.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32085=[""].join("\n");
var outline_f31_21_32085=null;
var title_f31_21_32086="Med bronchogen cyst CXR VI";
var content_f31_21_32086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70209%7EPULM%2F63014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70209%7EPULM%2F63014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic cyst adjacent to aortic arch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows mass adjacent to the aortic arch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic cyst adjacent to aortic arch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a cystic mass in close apposition to the distal aortic arch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32086=[""].join("\n");
var outline_f31_21_32086=null;
var title_f31_21_32087="Prediction of type 1 diabetes mellitus";
var content_f31_21_32087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prediction of type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     Massimo Pietropaolo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32087/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/21/32087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in understanding of the pathogenesis of type 1 diabetes mellitus (formerly known as insulin-dependent diabetes mellitus) has made it possible to consider intervention to slow the autoimmune disease process in an attempt to delay or even prevent the onset of hyperglycemia (",
"    <a class=\"graphic graphic_figure graphicRef63541 \" href=\"mobipreview.htm?6/23/6527\">",
"     figure 1",
"    </a>",
"    ). Although no successful strategy for the prevention of type 1 diabetes has yet been identified, subjects who are at high risk for type 1 diabetes can be identified using a combination of immune, genetic, and metabolic markers. This topic will review the use of genetic, immunologic, and metabolic markers to predict type 1 diabetes. The definition, pathogenesis, and prevention of type 1 diabetes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=see_link\">",
"     \"Prevention of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANIMAL MODELS OF TYPE 1 DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of two animal models of type 1 diabetes has made it possible to evaluate plausible therapeutic strategies before starting human trials. Non-obese diabetic (NOD) mice and BioBreeding (BB) rats are in-bred strains that spontaneously develop autoimmune insulitis and diabetes with striking similarities to type 1 diabetes in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The cumulative incidence of type 1 diabetes in these animals is high, and the onset of insulitis as well as hyperglycemia can be readily detected. Several interventions have been tested in these animals, often at a very early stage in the autoimmune disease process before the onset of insulitis. Examples include subcutaneous and oral insulin, nicotinamide, and the &szlig;-cell antigen glutamic acid decarboxylase. Of note, many interventions have been effective in the murine models when applied before the development of hyperglycemia; however, very few interventions have reversed established diabetes.",
"   </p>",
"   <p>",
"    Strategies for prevention or reversal of diabetes in animal models and in humans are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=see_link\">",
"     \"Prevention of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF PRECLINICAL TYPE 1 DIABETES IN HUMANS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes is usually caused by autoimmune destruction of the insulin-producing &szlig;-cells in the islets of Langerhans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/5\">",
"     5",
"    </a>",
"    ]. In the new classification of diabetes, immune mediated type 1 diabetes is called type 1A to distinguish it from some rarer cases in which an autoimmune etiology cannot be determined (type 1B); the latter are said to be idiopathic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/6\">",
"     6",
"    </a>",
"    ]. The term type 1 diabetes used here refers to type 1A, or autoimmune diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 1 diabetes occurs in genetically susceptible subjects. It is probably triggered by one or more environmental agents, and usually progresses over many months or years, during most of which the subject is asymptomatic and euglycemic (",
"    <a class=\"graphic graphic_figure graphicRef66417 \" href=\"mobipreview.htm?20/12/20686\">",
"     figure 2",
"    </a>",
"    ). A large percentage of the functioning &szlig;-cells must be lost before hyperglycemia appears.",
"   </p>",
"   <p>",
"    However, several aspects of the natural history of preclinical type 1 diabetes remain unclear, including the rate of progression and the changes in and predictive value of genetic and metabolic markers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rate of progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of progression of the immune injury is highly variable, even among high-risk subjects who have one or more of the relevant serum autoantibodies. In some subjects, as an example, progression is so slow that diabetes does not occur for many years or perhaps ever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. These subjects presumably regain tolerance in some way, eg, suppressor T cells become more numerous or helper T cells become less numerous or active. One report described a 10-year follow-up in 18 nondiabetic twins of type 1 diabetes probands: the eight twins who developed diabetes had persistently high numbers of CD8 HLA DR+ T-cells, whereas the 10 twins who remained euglycemic did not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, NOD mice that do not develop diabetes have regulatory T cells that suppress autoimmune destruction of the islets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, suppression of insulitis and protection from the development of diabetes can be achieved by injecting insulin-reactive CD4 T-cell clones from mice that do not develop diabetes into mice that would otherwise have developed diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This variability in progression of injury causes a major therapeutic dilemma with respect to intervention during the preclinical period. Early therapy is likely to preserve more &szlig; cells, but may also result in some patients being treated unnecessarily. There is also concern that treatment of a subject in whom the disease is not progressing might increase the risk of type 1 diabetes by disrupting the balance between helper and suppressor activity, a sequence that has been demonstrated in BB rats and NOD mice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, delaying therapy runs the risk that fewer &szlig; cells will be left to preserve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     USE OF MARKERS TO PREDICT TYPE 1 DIABETES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic markers may be helpful in assessing the risk of type 1 diabetes in close relatives of a patient with type 1 diabetes. The risk is markedly increased in these relatives, averaging about 6 percent in offspring and 5 percent in siblings (versus 0.4 percent in subjects with no family history) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk in siblings is importantly influenced by the degree of genetic similarity, falling from 33 percent in identical twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/5\">",
"     5",
"    </a>",
"    ] to 12.9 to 4.5 to 1.8 percent, respectively, if the siblings share two, one, or no haplotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major susceptibility genes for type 1 diabetes are in the HLA region on chromosome 6p [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/14\">",
"     14",
"    </a>",
"    ]. Over 90 percent of patients with type 1 diabetes carry DR4, DQB*0302",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DR3, DQB*0201. Thus, if the proband is heterozygous for DR3 and DR4 (the highest risk combination), the incidence of type 1 diabetes in a sibling who shares these two haplotypes rises to 19 percent. On the other hand, the absence of the above alleles makes type 1 diabetes very unlikely, especially if the subject carries a protective allele such as DQB*0301, *0602 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/15\">",
"     15",
"    </a>",
"    ], DRB*0403, or *0406 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combined effect of susceptibility or protective alleles and the presence or absence of a first-degree relative with type 1 diabetes is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef74366 \" href=\"mobipreview.htm?35/40/36491\">",
"     table 1",
"    </a>",
"    ). Use of genetic markers plus the family history make it possible to estimate the risk of type 1 diabetes as being as low as 1 in 5000 (no susceptibility alleles or family history) to as high as one in four (two susceptibility alleles and a positive family history). However, the prevalence of the HLA susceptibility genes is relatively high in whites. As a result, the predictive value of HLA typing is much lower in population screening than it is among families in which one or more members have type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, the risk for islet autoimmunity drastically increased in",
"    <span class=\"nowrap\">",
"     DR3/4-DQ2/DQ8",
"    </span>",
"    siblings who shared both HLA haplotypes identical by descent with their diabetic proband sibling (63 and 85 percent by ages 7 and 15, respectively) as compared with siblings who did not share both HLA haplotypes with their diabetic proband sibling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/18\">",
"     18",
"    </a>",
"    ]. These data suggest that HLA genotyping at birth may identify individuals at very high risk of developing type 1 diabetes before the occurrence of clear signs of islet autoimmunity and type 1 diabetes onset. Rapid automated assays make it possible to do large-scale population screening for HLA easily, even in newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the additional measurement of 2 HLA-DQ high-risk haplotypes does not increase the predictive value of combined autoantibody assays. However, in relatives who are seronegative for conventional islet autoantibodies, the presence of two HLA-DQ high-risk haplotypes is associated with an increased risk of progression to type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/21\">",
"     21",
"    </a>",
"    ]. This observation suggests that unidentified autoimmune phenomena may be present in seronegative relatives who carry the 2 HLA-DQ high-risk haplotypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunologic markers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinically useful serum autoantibodies can be detected during the preclinical period of type 1 diabetes, including islet-cell antibodies (ICA), insulin autoantibodies (IAA), antibodies to glutamic acid decarboxylase (GAD), and antibodies to tyrosine phosphatase-like proteins such as insulinoma associated protein (IA-2, ICA512) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In several prospective family studies (including the large combined data set of the Islet Cell Antibody Registry Users Study [ICARUS]) in which unaffected first-degree relatives of patients with type 1 diabetes were followed, the presence of ICA was associated with an increased risk of diabetes, particularly if the ICA titer was high, ICA were persistently detected, or ICA were present in combination with IAA or GAD antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have been reported with IA-2. In one study of first-degree relatives of type 1 diabetic probands, those with IA-2 autoantibodies in the upper three quartiles were at higher risk than relatives with an IA-2 autoantibody titer in the lowest quartile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/25\">",
"     25",
"    </a>",
"    ]. In another study, an autoantibody response directed to the extracellular domain of IA-2 was associated with very high risk of type 1 diabetes progression, suggesting the presence of new antigenic determinants within the extracellular domain of IA-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/26\">",
"     26",
"    </a>",
"    ]. This has considerable implications not only for stratifying high type 1 diabetes risk, but also to facilitate the search for pathogenic epitopes to enable the design of peptide-based immunotherapies, which may prevent the progression to overt type 1 diabetes at its preclinical stages.",
"   </p>",
"   <p>",
"    Unlike NOD mice, humans exhibit any combination of ICA, IAA, GAD, and IA-2 antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/10,27,28\">",
"     10,27,28",
"    </a>",
"    ]. The risk of type 1 diabetes is relatively low with IAA alone, but is higher with the presence of multiple autoantibodies against islet antigens (insulin, GAD, IA-2 and ICA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/21,24,29-31\">",
"     21,24,29-31",
"    </a>",
"    ]. Antibodies to GAD are predictive of progression to hyperglycemia even in the absence of ICA or IAA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/23\">",
"     23",
"    </a>",
"    ]. As with IAA, however, the risk is higher in subjects who are ICA-positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The titer of IAA has been used to predict the time to onset of type 1 diabetes, particularly in children younger than five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/32\">",
"     32",
"    </a>",
"    ]. In a prospective, cohort study of 1353 offspring of parents with type 1 diabetes, antibodies detected in the first six months were derived by placental transfer from the mother. Autoantibodies began to appear by nine months and frequently persisted. IAA were almost always the first to appear, with other antibodies (ICA, GAD, or IA-2) appearing later. By age five years, nine (1.8 percent) children had developed type 1 diabetes, and all had one or more autoantibodies beforehand. Fifty percent of children who had two or more antibodies present by two years had diabetes by age five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/33\">",
"     33",
"    </a>",
"    ]. In a follow-up report of a slightly larger cohort (1610 offspring), the following results were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By age five years, the frequencies of islet autoantibodies, multiple autoantibodies, and type 1 diabetes were 5.9, 3.5, and 1.5 percent, respectively.",
"     </li>",
"     <li>",
"      The risk of diabetes was highest in those with multiple autoantibodies (40 percent within five years versus 3 percent in those with single autoantibodies).",
"     </li>",
"     <li>",
"      Progression to multiple islet autoantibodies was fastest in children who developed their first autoantibody by age two years.",
"     </li>",
"     <li>",
"      The risk of progression to diabetes was inversely related to the age of positivity for multiple islet autoantibodies (50 percent of children who had multiple positivity before age nine months developed diabetes within two years, compared with 7 percent in those who had multiple autoantibodies at age five years).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, children with the earliest evidence of autoimmunity are at greatest risk for and progress more quickly to the development of type 1 diabetes. Periodic testing for islet autoantibodies appears to help assess the risk of diabetes in children of parents with type 1 diabetes.",
"   </p>",
"   <p>",
"    In another study of 81 Swedish children who later developed type 1 diabetes, 14 (17 percent) had at least one autoantibody present at birth (either GAD, IAA, or ICA512), as compared with 12 of 320 (4 percent) control children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/35\">",
"     35",
"    </a>",
"    ]. Four percent had more than one autoantibody present, compared with none of the control children. This study suggests that the autoimmune process may start in utero, but that this is rare.",
"   </p>",
"   <p>",
"    In addition to identifying subjects at risk for type 1 diabetes, the presence of ICA and GAD antibodies can also identify late-onset type 1 diabetes in adults thought to have type 2 diabetes. In a study of 97 Swedish diabetic patients who were initially thought to have type 2 or unclassifiable diabetes, 70 became insulin-dependent after six years of follow-up. Among these 70 patients, 60 percent were positive for either ICA or GAD at diagnosis, compared with only 2 percent of the 27 patients who remained responsive to oral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of these serological markers was closely correlated with histological evidence of insulitis in a study of 29 patients with recently diagnosed type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/37\">",
"     37",
"    </a>",
"    ]. Pancreatic biopsies obtained within these months of diagnosis revealed a T-cell infiltration of pancreatic islets and hyperexpression of HLA class I antigens on islet cells. These features were much more evident among patients with high serum ICA concentration, or the presence of GAD, IAA, or multiple antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Zinc transporter antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cation efflux zinc transporter (ZnT8) has also been identified as a candidate type 1 diabetes autoantigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/38\">",
"     38",
"    </a>",
"    ]. Sixty to 80 percent of patients with newly diagnosed type 1 diabetes have ZnT8 autoantibodies. In addition, 26 percent of subjects with antibody negative (insulin, GAD, IA-2 and ICA) type 1 diabetes have ZnT8 autoantibodies.",
"   </p>",
"   <p>",
"    The function of this transporter is unknown. The finding of a polymorphism within the ZnT8 locus in patients with type 2 diabetes suggests that alterations in the function of this gene may result in abnormal effects on insulin secretion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insulin response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Insulin release'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Insulin action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Screening low risk populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 diabetes mellitus can also be predicted in children without familial diabetes. In a study of 4505 healthy schoolchildren, measurement of autoantibodies (GAD, IAA, and",
"    <span class=\"nowrap\">",
"     IA2/ICA512)",
"    </span>",
"    prospectively identified all children who developed diabetes within eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the prediction of rare diseases such as type 1 diabetes is a difficult undertaking (estimated prevalence = 1.2 to",
"    <span class=\"nowrap\">",
"     1.5/1000",
"    </span>",
"    in the United States) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/40\">",
"     40",
"    </a>",
"    ]. We would anticipate that a large proportion of individuals with positive screening test results, including multiple autoantibodies to islet antigens, will inevitably be found not to have the disease upon further diagnostic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/41\">",
"     41",
"    </a>",
"    ]. As an example, in a study in healthy French schoolchildren who were screened with islet antibody markers, the number of children with positive ICA was 40 times greater than the number of cases in the cohort expected to develop type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although glucose tolerance remains normal until close to the onset of hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/43\">",
"     43",
"    </a>",
"    ], the acute insulin response to several secretagogues (glucose, arginine, glucagon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    ) decreases progressively during the preclinical period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/44\">",
"     44",
"    </a>",
"    ]. The most useful and widely performed test is the acute (or \"first phase\") insulin response to glucose (FPIR) during an intravenous glucose tolerance test (IVGTT); in this test the rise in serum insulin above baseline is measured during the first 10 minutes after an intravenous glucose challenge; the response correlates with the functioning &szlig;-cell mass (",
"    <a class=\"graphic graphic_figure graphicRef54816 \" href=\"mobipreview.htm?38/15/39166\">",
"     figure 3",
"    </a>",
"    ). The IVGTT has been standardized to allow easier comparison between centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In first-degree relatives of patients with type 1 diabetes, for example, an FPIR below the first percentile of normal is a strong predictor of type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1), subjects at high risk for developing diabetes were followed with serial IVGTTs and oral glucose tolerance tests (OGTTs), and in a subsequent study, the metabolic factors associated with progression to diabetes were evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities of FPIR and two-hour glucose during OGTT had similar sensitivities for diabetes prediction within six months of diagnosis (76 percent for OGTT [95% CI 60 to 83 percent] and 73 percent for FPIR [95% CI 60 to 83 percent]). Sensitivity was better when both tests were performed, and the vast majority of these individuals (97 percent) had abnormal IVGTTs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    OGTTs before the development of the overt diabetes. In contrast, fasting blood glucose levels were a poor predictor of diabetes.",
"   </p>",
"   <p>",
"    A simpler test that may prove useful is to measure the fasting serum concentration of proinsulin, the precursor of insulin. In normal subjects, proinsulin accounts for approximately 15 percent of serum immunoreactive insulin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/48\">",
"     48",
"    </a>",
"    ]. This proportion rises as &szlig;-cell function declines. One report, as an example, found that serum proinsulin concentrations were three to four times higher among ICA-positive relatives of type 1 diabetes patients as compared with ICA-negative relatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32087/abstract/49\">",
"     49",
"    </a>",
"    ]. However, prospective studies are needed to determine whether elevated serum proinsulin values will help in predicting the development of type 1 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the prevention of type 1 diabetes is still at the stage of research trials, the trials are often mentioned in the lay press. As a result, many patients with type 1 diabetes (or their parents) ask their doctors about screening of other family members (particularly children) and what could be done if the family member has a high risk for the development of type 1 diabetes.",
"   </p>",
"   <p>",
"    In a research setting, the following approach may be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Test individuals at risk for type 1 diabetes progression for GAD65 and IA-2 autoantibodies.",
"     </li>",
"     <li>",
"      If they are present and confirmed in a subsequent sample, tests for insulin, zinc transporter (ZnT8), and islet cell antibodies can be done and the first phase insulin response to glucose (FPIR) determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The occurrence of multiple antibodies against islet autoantigens serves as a surrogate marker of disease in primary or secondary intervention strategies aimed at halting the disease process.",
"   </p>",
"   <p>",
"    Genetic typing for susceptibility or protective HLA alleles can also be performed. In the aggregate, this information can be used to ascertain if a high-risk subject is eligible to be entered into an ongoing prevention trial.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/1\">",
"      Mordes JP, Desemone J, Rossini AA. The BB rat. Diabetes Metab Rev 1987; 3:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/2\">",
"      Kolb H. Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev 1987; 3:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/3\">",
"      Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994; 343:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/4\">",
"      Shehadeh N, Calcinaro F, Bradley BJ, et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994; 343:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/5\">",
"      Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/6\">",
"      Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/7\">",
"      McCulloch DK, Klaff LJ, Kahn SE, et al. Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study. Diabetes 1990; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/8\">",
"      B&auml;rmeier H, McCulloch DK, Neifing JL, et al. Risk for developing type 1 (insulin-dependent) diabetes mellitus and the presence of islet 64K antibodies. Diabetologia 1991; 34:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/9\">",
"      Tarn AC, Thomas JM, Dean BM, et al. Predicting insulin-dependent diabetes. Lancet 1988; 1:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/10\">",
"      Greenbaum CJ, Sears KL, Kahn SE, Palmer JP. Relationship of beta-cell function and autoantibodies to progression and nonprogression of subclinical type 1 diabetes: follow-up of the Seattle Family Study. Diabetes 1999; 48:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/11\">",
"      Peakman M, Leslie RD, Alviggi L, et al. Persistent activation of CD8+ T-cells characterizes prediabetic twins. Diabetes Care 1996; 19:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/12\">",
"      Semp&eacute; P, Richard MF, Bach JF, Boitard C. Evidence of CD4+ regulatory T cells in the non-obese diabetic male mouse. Diabetologia 1994; 37:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/13\">",
"      Zekzer D, Wong FS, Wen L, et al. Inhibition of diabetes by an insulin-reactive CD4 T-cell clone in the nonobese diabetic mouse. Diabetes 1997; 46:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/14\">",
"      Thomson G, Robinson WP, Kuhner MK, et al. Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am J Hum Genet 1988; 43:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/15\">",
"      Pugliese A, Gianani R, Moromisato R, et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 1995; 44:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/16\">",
"      Undlien DE, Friede T, Rammensee HG, et al. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 1997; 46:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/17\">",
"      Bingley PJ, Bonifacio E, Gale EA. Can we really predict IDDM? Diabetes 1993; 42:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/18\">",
"      Aly TA, Ide A, Jahromi MM, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A 2006; 103:14074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/19\">",
"      Rewers M, Bugawan TL, Norris JM, et al. Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY). Diabetologia 1996; 39:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/20\">",
"      Ilonen J, Reijonen H, Herva E, et al. Rapid HLA-DQB1 genotyping for four alleles in the assessment of risk for IDDM in the Finnish population. The Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 1996; 19:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/21\">",
"      Pietropaolo M, Becker DJ, LaPorte RE, et al. Progression to insulin-requiring diabetes in seronegative prediabetic subjects: the role of two HLA-DQ high-risk haplotypes. Diabetologia 2002; 45:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/22\">",
"      Pietropaolo M, Eisenbarth GS. Autoantibodies in human diabetes. Curr Dir Autoimmun 2001; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/23\">",
"      Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/24\">",
"      Bingley PJ. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study. Diabetes 1996; 45:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/25\">",
"      Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004; 53:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/26\">",
"      Morran MP, Casu A, Arena VC, et al. Humoral autoimmunity against the extracellular domain of the neuroendocrine autoantigen IA-2 heightens the risk of type 1 diabetes. Endocrinology 2010; 151:2528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/27\">",
"      Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/28\">",
"      Tisch R, Yang XD, Singer SM, et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/29\">",
"      Neifing JL, Greenbaum CJ, Kahn SE, et al. Prospective evaluation of beta-cell function in insulin autoantibody-positive relatives of insulin-dependent diabetic patients. Metabolism 1993; 42:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/30\">",
"      Dean BM, Becker F, McNally JM, et al. Insulin autoantibodies in the pre-diabetic period: correlation with islet cell antibodies and development of diabetes. Diabetologia 1986; 29:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/31\">",
"      Srikanta S, Ricker AT, McCulloch DK, et al. Autoimmunity to insulin, beta cell dysfunction, and development of insulin-dependent diabetes mellitus. Diabetes 1986; 35:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/32\">",
"      Ziegler AG, Ziegler R, Vardi P, et al. Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with type I diabetes. Diabetes 1989; 38:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/33\">",
"      Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 1999; 48:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/34\">",
"      Hummel M, Bonifacio E, Schmid S, et al. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med 2004; 140:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/35\">",
"      Lindberg B, Ivarsson SA, Landin-Olsson M, et al. Islet autoantibodies in cord blood from children who developed type I (insulin-dependent) diabetes mellitus before 15 years of age. Diabetologia 1999; 42:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/36\">",
"      Littorin B, Sundkvist G, Hagopian W, et al. Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care 1999; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/37\">",
"      Imagawa A, Hanafusa T, Tamura S, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 2001; 50:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/38\">",
"      Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104:17040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/39\">",
"      LaGasse JM, Brantley MS, Leech NJ, et al. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study. Diabetes Care 2002; 25:505.",
"     </a>",
"    </li>",
"    <li>",
"     Dorman JS, McCarthy BJ, O'Leary LA, Koehler AN. Risk factors for insulin-dependent diabetes. In: Diabetes in America, 2nd, Aubert R (Ed), Diane Pub Co., 1995. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/41\">",
"      Pietropaolo M, Becker DJ. Type 1 diabetes intervention trials. Pediatr Diabetes 2001; 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/42\">",
"      Ongagna JC, Levy-Marchal C. Sensitivity at diagnosis of combined beta-cell autoantibodies in insulin-dependent diabetic children. French Registry of IDDM in Children Study Group. Diabetes Metab 1997; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/43\">",
"      Atkinson MA, Maclaren NK, Scharp DW, et al. 64,000 Mr autoantibodies as predictors of insulin-dependent diabetes. Lancet 1990; 335:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/44\">",
"      Aanstoot HJ, Sigurdsson E, Jaffe M, et al. Value of antibodies to GAD65 combined with islet cell cytoplasmic antibodies for predicting IDDM in a childhood population. Diabetologia 1994; 37:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/45\">",
"      Bingley PJ, Colman P, Eisenbarth GS, et al. Standardization of IVGTT to predict IDDM. Diabetes Care 1992; 15:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/46\">",
"      McCulloch DK, Bingley PJ, Colman PG, et al. Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. The ICARUS Group. Islet Cell Antibody Register User's Study. Diabetes Care 1993; 16:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/47\">",
"      Barker JM, McFann K, Harrison LC, et al. Pre-type 1 diabetes dysmetabolism: maximal sensitivity achieved with both oral and intravenous glucose tolerance testing. J Pediatr 2007; 150:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/48\">",
"      Ward WK, LaCava EC, Paquette TL, et al. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32087/abstract/49\">",
"      Spinas GA, Snorgaard O, Hartling SG, et al. Elevated proinsulin levels related to islet cell antibodies in first-degree relatives of IDDM patients. Diabetes Care 1992; 15:632.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1791 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32087=[""].join("\n");
var outline_f31_21_32087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANIMAL MODELS OF TYPE 1 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NATURAL HISTORY OF PRECLINICAL TYPE 1 DIABETES IN HUMANS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rate of progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      USE OF MARKERS TO PREDICT TYPE 1 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunologic markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Zinc transporter antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Screening low risk populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolic markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1791\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1791|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/23/6527\" title=\"figure 1\">",
"      Antigen presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/12/20686\" title=\"figure 2\">",
"      Course of IDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/15/39166\" title=\"figure 3\">",
"      Acute insulin response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1791|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/40/36491\" title=\"table 1\">",
"      Genetic markers in IDDM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/5/13401?source=related_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_21_32088="Repetitive monomorphic VT";
var content_f31_21_32088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Telemetry recording (lead II) from a patient with RMVT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Repetitive monomorphic ventricular tachycardia (RMVT) is characterized by frequent short \"salvos\" or bursts of monomorphic nonsustained VT. The bursts may vary in duration, but all demonstrate the same QRS morphology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32088=[""].join("\n");
var outline_f31_21_32088=null;
var title_f31_21_32089="Genetics of Alzheimer disease";
var content_f31_21_32089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics of Alzheimer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     Rick Sherva, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     Neil W Kowall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32089/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/21/32089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6562986\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alzheimer disease (AD) is the most common form of dementia, with an estimated lifetime risk of nearly one in five for women and 1 in 10 for men. AD is highly heritable, even in so-called sporadic cases. The genetic basis for AD is best understood in the early-onset form, which accounts for less than one percent of cases and typically follows an autosomal dominant inheritance pattern related to mutations in genes that alter amyloid-beta (A&beta;) protein production, aggregation, or clearance. The genetic basis of late-onset AD is more complex, with susceptibility likely conferred by a variety of more common but less penetrant genetic factors, such as apolipoprotein E (",
"    <em>",
"     APOE",
"    </em>",
"    ) alleles, interacting with environmental and epigenetic influences.",
"   </p>",
"   <p>",
"    This topic will review the genetic basis of AD in both early-onset and late-onset forms. Other risk factors for dementia and the clinical manifestations and diagnosis of AD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=see_link\">",
"     \"Risk factors for dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025787\">",
"    <span class=\"h1\">",
"     APPROACHES TO GENE DISCOVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic contribution to Alzheimer disease (AD) risk remains poorly understood despite major advances in the 1990&rsquo;s in the identification of three genes that cause early-onset familial AD and one genetic risk factor for late-onset AD (LOAD). There have been three main strategies employed to identify genetic factors that predispose to the development of AD: linkage analysis, candidate gene studies, and genome-wide association studies. General principles of genetic variation and genetic association studies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1027823\">",
"    <span class=\"h2\">",
"     Linkage analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first progress in understanding the genetic basis of AD resulted from studies of families displaying autosomal dominant inheritance of the disorder. These studies used linkage-based methodology, in which a relatively small number (on the order of several hundred) of non-functional genetic markers spaced throughout the genome are genotyped in order to determine whether a given section of chromosome was transmitted from parents to their offspring. By comparing this information to disease status, the genes responsible can be mapped to relatively large chromosomal regions. Early AD studies used linkage analysis to identify culprit regions on chromosomes 1, 14, and 21, eventually leading to discovery of the three known causative AD genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6562978\">",
"     'Early-onset Alzheimer Disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Whereas linkage analysis has been very successful in identifying monogenic traits in early-onset familial AD, it has had much more limited success in late-onset AD, which is more likely to be a complex trait. (See",
"    <a class=\"local\" href=\"#H900049\">",
"     'Challenges'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025837\">",
"    <span class=\"h2\">",
"     Candidate gene studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidate gene studies can include family members or unrelated individuals and require some degree of foreknowledge about the genes and pathways involved in AD. In this approach, one or a small number of known genetic variants, called single nucleotide polymorphisms (SNPs) are genotyped and compared in cases and controls. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drawing on clues about AD pathogenesis emerging from cell biology and neurochemistry, numerous candidate gene association studies have been conducted in AD. Studies typically focus on loci with potential effects on amyloid-beta production, aggregation or clearance (ie, a functional hypothesis) or on loci suspected to be important based on prior linkage studies (ie, a positional hypothesis). &nbsp;",
"   </p>",
"   <p>",
"    The primary success of the candidate gene approach in LOAD has been the identification of",
"    <em>",
"     APOE",
"    </em>",
"    risk alleles (whose location was identified originally through linkage studies). Subsequently, nearly 700 other candidate genes have been investigated based on functional hypotheses, with mostly inconsistent results. (See",
"    <a class=\"local\" href=\"#H899448\">",
"     'Apolipoprotein E'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H899456\">",
"     'Other candidate genes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As exome and whole-genome sequencing becomes more feasible and cost efficient, the candidate gene approach may yield further insights into the heritability of LOAD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1025931\">",
"    <span class=\"h2\">",
"     Genome-wide association studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first decade of the 21",
"    <sup>",
"     st",
"    </sup>",
"    century, microarray technology revolutionized genetics research, making it possible to test hundreds of thousands of candidate genes simultaneously. Such genome-wide association studies (GWAS) allow for large-scale, largely hypothesis-free inquiries aimed at identifying novel genetic risk factors for AD.",
"   </p>",
"   <p>",
"    In AD, multiple GWAS have been performed to date, largely confirming the importance of",
"    <em>",
"     APOE",
"    </em>",
"    and implicating a growing number of other potential loci. (See",
"    <a class=\"local\" href=\"#H899456\">",
"     'Other candidate genes'",
"    </a>",
"    below.) To date, information from over 1375 candidate gene and genome-wide association studies, implicating nearly 700 candidate genes, has been curated by the Alzheimer Disease Forum in the",
"    <a class=\"external\" href=\"file://www.alzforum.org/res/com/gen/alzgene\">",
"     AlzGene database",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6562978\">",
"    <span class=\"h1\">",
"     EARLY-ONSET ALZHEIMER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first progress in understanding the genetic basis of Alzheimer disease (AD) resulted from studies of families displaying autosomal dominant inheritance of the disorder. Families with autosomal dominant AD are those with at least three affected individuals in two or more generations, with two of the individuals being first-degree relatives of the third. In these families, affected individuals typically develop symptoms of AD between the ages of 30 and 60 years. Most, but not all, families with early-onset AD show an autosomal dominant pattern of inheritance. The pattern may be masked in small families or those with premature deaths (ie, prior to the age of risk onset) from unrelated causes.",
"   </p>",
"   <p>",
"    Early studies in families with autosomal dominant AD used linkage-based methodology to isolate relatively large culprit regions on chromosomes 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/1\">",
"     1",
"    </a>",
"    ], 14 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], and 21 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/4\">",
"     4",
"    </a>",
"    ]. This facilitated the eventual identification of causative mutations in the three genes: amyloid precursor protein (",
"    <em>",
"     APP",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/6\">",
"     6",
"    </a>",
"    ], presenilin 1 (",
"    <em>",
"     PSEN1",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/7\">",
"     7",
"    </a>",
"    ], and presenilin 2 (",
"    <em>",
"     PSEN2",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Although these mutations collectively account for less than 1 percent of all AD cases and 60 to 70 percent of early-onset AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], their discovery substantially increased the understanding of basic AD pathophysiology. A resource for the tabulation of",
"    <em>",
"     APP",
"    </em>",
"    ,",
"    <em>",
"     PSEN1",
"    </em>",
"    , and",
"    <em>",
"     PSEN2",
"    </em>",
"    mutations associated with AD is the",
"    <a class=\"external\" href=\"file://www.molgen.ua.ac.be/ADMutations\">",
"     Alzheimer Disease and Frontotemporal Dementia Database",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2663392\">",
"    <span class=\"h2\">",
"     Amyloid precursor protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <em>",
"     APP",
"    </em>",
"    gene is located on chromosome 21q and encodes the protein product, APP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/13\">",
"     13",
"    </a>",
"    ]. More than 30 mutations in this gene have been described in association with AD, accounting for 10 to 15 percent of early-onset familial AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Mutations are fully penetrant, although the age of symptom onset can vary within families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/11\">",
"     11",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The function of APP in neurons is not well understood, but it is believed to be important in synaptic transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/14\">",
"     14",
"    </a>",
"    ]. APP is proteolytically cleaved by three enzymes, known as &alpha;-, &beta;-, and &gamma;-secretase. In the amyloidogenic pathway, &beta;-secretase and later &gamma;-secretase cleaves APP into two peptides of varying lengths. The longer of the two fragments, A&beta;42, is more hydrophobic and prone to fibril formation.",
"   </p>",
"   <p>",
"    Nearly all pathogenic",
"    <em>",
"     APP",
"    </em>",
"    mutations identified so far cluster around the three major processing sites that are relevant to the generation of amyloidogenic A&szlig;, increasing production of A&beta; or altering the ratio of A&beta;42 to A&beta;40 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Most are dominant missense mutations, although rare families with",
"    <em>",
"     APP",
"    </em>",
"    locus duplication or recessive inheritance patterns have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2663399\">",
"    <span class=\"h2\">",
"     Presenilin 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <em>",
"     PSEN1",
"    </em>",
"    gene is located on chromosome 14q and encodes the protein product, PSEN1. More than 150",
"    <em>",
"     PSEN1",
"    </em>",
"    mutations have been described in association with AD, accounting for up to 50 percent of early-onset familial AD. Mutations are fully penetrant with early yet somewhat variable age of onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several different functions have been ascribed to PSEN1, including regulation of intracellular calcium signaling, cell cycle and cell death, trafficking of membrane proteins, regulation of &beta;-catenin stability, and Notch signaling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/24\">",
"     24",
"    </a>",
"    ]. PSEN1 likely affects AD pathogenesis through its role as a member of the four-protein complex (PSEN1, APH1, PEN2, nicastrin) responsible for &gamma;-secretase cleavage of APP to release A&beta; peptides of varying lengths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most mutations in PSEN1 increase the generation of the highly fibrillogenic A&beta;",
"    <sub>",
"     42",
"    </sub>",
"    species and enhance accumulation of A&beta; in the brain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/24\">",
"     24",
"    </a>",
"    ]. Blood and CSF levels of A&beta; are also elevated. The majority of",
"    <em>",
"     PSEN1",
"    </em>",
"    mutations are missense mutations, but small deletions and insertions have been described as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2663406\">",
"    <span class=\"h2\">",
"     Presenilin 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <em>",
"     PSEN2",
"    </em>",
"    gene is located on chromosome 1q and encodes the protein product, PSEN2. Fewer than 20",
"    <em>",
"     PSEN2",
"    </em>",
"    mutations have been described, making it the rarest form of early-onset familial AD. The age of onset varies more widely with",
"    <em>",
"     PSEN2",
"    </em>",
"    mutations than it does with mutations in",
"    <em>",
"     APP",
"    </em>",
"    or",
"    <em>",
"     PSEN1",
"    </em>",
"    . Mutations are estimated to be 95 percent penetrant, meaning that up to five percent of patients carrying a disease-causing mutation will not develop symptoms of AD in their lifetime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. This contrasts with",
"    <em>",
"     APP",
"    </em>",
"    and",
"    <em>",
"     PSEN1",
"    </em>",
"    mutations, which are felt to be fully penetrant.",
"   </p>",
"   <p>",
"    The function of PSEN2 and the role of",
"    <em>",
"     PSEN2",
"    </em>",
"    mutations in the pathogenesis of AD are not well understood.",
"    <em>",
"     PSEN2",
"    </em>",
"    mutations may act in part by enhancing apoptotic activity that leads to neurodegeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/30\">",
"     30",
"    </a>",
"    ]. Similar to",
"    <em>",
"     PSEN1",
"    </em>",
"    mutations,",
"    <em>",
"     PSEN2",
"    </em>",
"    mutations alter the cleavage activity of &gamma;-secretase and increase the ratio of A&beta;",
"    <sub>",
"     42",
"    </sub>",
"    to A&beta;",
"    <sub>",
"     40",
"    </sub>",
"    . PSEN2 is about 60 percent homologous to PSEN1, and may represent a very early chromosomal separation or partial duplication from the PSEN1 gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H912645\">",
"    <span class=\"h2\">",
"     Trisomy 21",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with trisomy 21 (Down syndrome) commonly develop clinical and neuropathological features of AD by the fifth decade of life due to the presence of an extra copy of the",
"    <em>",
"     APP",
"    </em>",
"    gene, which results in increased production of mRNA and subsequently APP protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2663413\">",
"    <span class=\"h1\">",
"     LATE-ONSET ALZHEIMER DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic basis of late-onset Alzheimer disease (LOAD) is more complex, with susceptibility conferred by a variety of more common but less penetrant genetic factors, likely interacting with environmental and epigenetic influences. To date, the only established genetic risk factor for late-onset disease is apoprotein E (",
"    <em>",
"     APOE",
"    </em>",
"    ). Many more candidate genes have been identified through genome-wide association studies (GWAS), but their contribution to LOAD risk remains uncertain and many have not been validated independently. Some of the more replicated candidate genes are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H899448\">",
"    <span class=\"h2\">",
"     Apolipoprotein E",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apolipoprotein E (",
"    <em>",
"     APOE",
"    </em>",
"    ) gene is located on chromosome 19 and exists in three alleles: epsilon 2, 3, and 4. The",
"    <em>",
"     APOE",
"    </em>",
"    epsilon 4 (&epsilon;4) allele was first recognized as a risk factor for LOAD in 1993 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/32\">",
"     32",
"    </a>",
"    ], and since then, multiple studies have confirmed its importance as a risk factor for AD and possibly vascular dementia as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/32-43\">",
"     32-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1026217\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of the",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 risk allele varies greatly across ethnic groups. In Caucasians, the allele frequency of the &epsilon;4 variant is approximately 15 percent; in African Americans, approximately 25 percent. Among African populations, the frequency ranges from 8 percent in Moroccans to as high as 41 percent in Pygmies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/44\">",
"     44",
"    </a>",
"    ]. Asian populations generally have low carrier rates, ranging from 7 percent in the Chinese to 24 percent in Malay Aborigines. Its increased frequency in populations where food is, or was in the recent past, scarce, suggests that &epsilon;4 is a &ldquo;thrifty&rdquo; allele that imparts a competitive advantage through energy",
"    <span class=\"nowrap\">",
"     conservation/utilization",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1026225\">",
"    <span class=\"h3\">",
"     Strength of association",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates for the increased risk conferred by the &epsilon;4 allele vary by population studied and differ based on age and gender. Individuals with two copies of the &epsilon;4 allele are at the highest risk. Typical estimates suggest that one &epsilon;4 allele confers two to three-fold increased odds of AD whereas two copies (&epsilon;4 homozygous) confer 8 to 12-fold increased odds of AD compared with non-carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/10,41,43\">",
"     10,41,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of studies demonstrating the association between",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 genotype and dementia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Rotterdam study, a population-based cohort of 7983 people aged 55 or older, carriers of the",
"      <span class=\"nowrap\">",
"       &epsilon;2/&epsilon;4",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       &epsilon;3/&epsilon;4",
"      </span>",
"      genotypes each had a relative risk of AD and vascular dementia that was about double that of",
"      <span class=\"nowrap\">",
"       &epsilon;3/&epsilon;3",
"      </span>",
"      carriers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/41\">",
"       41",
"      </a>",
"      ]. Carriers of the",
"      <span class=\"nowrap\">",
"       &epsilon;4/&epsilon;4",
"      </span>",
"      genotype had a relative risk of dementia about eight times that of",
"      <span class=\"nowrap\">",
"       &epsilon;3/&epsilon;3",
"      </span>",
"      carriers.",
"     </li>",
"     <li>",
"      In an analysis of 1030 elderly persons (&gt;70 years) in the Framingham study,",
"      <em>",
"       APOE",
"      </em>",
"      &epsilon;4 homozygotes had a 30.1 relative risk (95% CI 11-84) for AD compared to noncarriers, while",
"      <span class=\"nowrap\">",
"       &epsilon;3/&epsilon;4",
"      </span>",
"      heterozygotes had a relative risk of 3.7 (95% CI 1.9-7.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <em>",
"     APOE",
"    </em>",
"    is a susceptibility gene, not a determinative gene. Patients homozygous for this allele are much more likely but not absolutely destined to develop dementia. In addition, almost 40 percent of patients with AD do not carry",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence to suggest that",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 mediates at least some of its susceptibility to dementia by decreasing the age of onset of AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The mechanisms of action of",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 are compatible with earlier onset. However, some have noted an older age of onset of AD in",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 allele has also been associated with the severity of AD. Among the associations are earlier and faster cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/49\">",
"     49",
"    </a>",
"    ], increased hippocampal atrophy on MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/50,51\">",
"     50,51",
"    </a>",
"    ], more psychiatric complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/38,52\">",
"     38,52",
"    </a>",
"    ], more neuritic plaques and neurofibrillary tangles in all neocortical regions at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], and decreased survival time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 with either the incidence of mild cognitive impairment (MCI) or its progression to dementia is not well defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/45,55-57\">",
"     45,55-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=see_link\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26138?source=see_link&amp;anchor=H8#H8\">",
"     \"Mild cognitive impairment: Prognosis and treatment\", section on 'ApoE epsilon 4'",
"    </a>",
"    .) The",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 allele has also been associated with other precursor AD states as defined by neuroimaging and CSF studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/58-62\">",
"     58-62",
"    </a>",
"    ]. However the specificities of these precursor AD findings are not well defined.",
"   </p>",
"   <p>",
"    The risk associated with",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 may be modified by other genes or environmental factors. As an example, the Saitohin (STH) gene lies within an intron of the human tau gene and may have a role in regulating tau isoforms and thus neurofibrillary tangle deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. An STH gene A to G polymorphism appears to be overrepresented in patients with AD. While this may not be an independent risk factor for AD, the STH polymorphism may be associated with an increased risk of AD in the presence of the",
"    <em>",
"     APOE &epsilon;4",
"    </em>",
"    allele [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/64\">",
"     64",
"    </a>",
"    ]. Polymorphisms in other genes, such as complement component",
"    <span class=\"nowrap\">",
"     3b/4b",
"    </span>",
"    receptor-1 (CR1), appear to lower risk of AD among APOE &epsilon;4 carriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/65\">",
"     65",
"    </a>",
"    ]. Vascular risk factors (smoking, diabetes, hypertension, hypercholesterolemia) may also modify the risk of cognitive decline in individuals with",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strength of the association between",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 and AD or cognitive decline among African Americans and Africans is unclear. Studies examining this issue have had conflicting results, with some finding results similar to white populations and others finding a lower or even no association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/10,37,56,67-72\">",
"     10,37,56,67-72",
"    </a>",
"    ]. Possible explanations for these discrepancies include a lower mean age of the African American population in some studies, heterogeneity of African American subgroups at different study sites, and modification of",
"    <em>",
"     APOE",
"    </em>",
"    effect by environmental and genetic factors.",
"   </p>",
"   <p>",
"    There is also some evidence that the influence of",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 is modified by gender. A meta-analysis concluded that while",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 is a risk factor for AD in both men and women, the effect is higher in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the &epsilon;4 allele, epidemiologic as well as pathologic studies have suggested a possible protective effect for the &epsilon;2 allele in AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/43,53\">",
"     43,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1026240\">",
"    <span class=\"h3\">",
"     Proposed mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism whereby",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 influences the development of AD is not known and may involve multiple pathways. APOE is a prevalent lipoprotein in brain, involved in cholesterol homeostasis. It mediates neuronal protection and repair and is believed to participate in amyloid-beta deposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three APOE isoforms, &epsilon;2, &epsilon;3, and &epsilon;4, differ in amino acid sequence at residues 112 and 158. At these positions, the alleles &epsilon;2, &epsilon;3, and &epsilon;4 contain",
"    <span class=\"nowrap\">",
"     cysteine/cysteine,",
"    </span>",
"    <span class=\"nowrap\">",
"     cysteine/arginine,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     arginine/arginine,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/74,75\">",
"     74,75",
"    </a>",
"    ], with arginine increasing the overall charge on the protein. Functional studies have shown that oxidized &epsilon;4 binds amyloid-beta (A&beta;) much more rapidly than does &epsilon;3 and might affect the sequestration of A&beta; in plaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/76\">",
"     76",
"    </a>",
"    ]. Alternately, or in addition to this pathway, APOE isoforms bind differentially to microtubule-associated protein tau (MAPT), the major component of neurofibrillary tangles, indicating that APOE could affect microtubule function and tangle formation in AD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/77\">",
"     77",
"    </a>",
"    ]. Furthermore, the isoforms differentially affect choline acetyltransferase activity in the hippocampus of AD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/78\">",
"     78",
"    </a>",
"    ] and may also alter the lipid transport system associated with compensatory sprouting and synaptic remodeling following AD-associated brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. APOE variants have also been associated with cortisol level in cerebral spinal fluid, which might lower the threshold for neuronal degeneration in AD patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 also affects plasma lipid levels and is associated with atherosclerotic vascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/82\">",
"     82",
"    </a>",
"    ]. In a case control study, high concentrations of plasma lipoprotein(a) increased the risk of developing late-onset AD in carriers of the &epsilon;4 allele, but not in noncarriers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/83\">",
"     83",
"    </a>",
"    ]. However, in a prospective cohort study,",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 was a risk factor for AD, independent from cholesterol, lipid and lipoprotein levels, suggesting that vascular disease is not the primary mechanism by which",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 influences the development of AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1026606\">",
"    <span class=\"h3\">",
"     Diagnostic utility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotyping of",
"    <em>",
"     APOE",
"    </em>",
"    adds marginally to the predictive value of clinical criteria for AD and may stratify risk of conversion of amnesic MCI to AD, but both false positives and negatives occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. It is therefore not recommended except as part of a research protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H899456\">",
"    <span class=\"h2\">",
"     Other candidate genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from APOE, more than 20 other genes have been identified through individual candidate gene studies or GWAS and shown to have statistically significant risk effects in later meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. The average allelic summary odds ratios for these candidates are modest, ranging from 1.1 to 1.5, compared with a single",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4 allele, which confers an approximately fourfold increased odds of disease.",
"   </p>",
"   <p>",
"    Some representative meta-analyses and their findings apart from",
"    <em>",
"     APOE",
"    </em>",
"    -related risk include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alzheimer GWAS cohorts from across Europe were pooled to include a total of 6010 cases and 8625 controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/87\">",
"       87",
"      </a>",
"      ]. Genome-wide significant associations were found with SNPs in clusterin (",
"      <em>",
"       CLU",
"      </em>",
"      ), also known as",
"      <em>",
"       APOJ",
"      </em>",
"      , and complement component",
"      <span class=\"nowrap\">",
"       3b/4b",
"      </span>",
"      receptor 1 (",
"      <em>",
"       CR1",
"      </em>",
"      ).",
"     </li>",
"     <li>",
"      In a pooled analysis of 16,000 participants recruited through different AD studies in the US and Europe, genome-wide significant associations were identified with SNPs in",
"      <em>",
"       CLU",
"      </em>",
"      and phosphatidylinositol-binding clathrin assembly protein (",
"      <em>",
"       PICALM",
"      </em>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combined data from Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) and several European cohorts also confirmed significant effects of",
"      <em>",
"       CLU",
"      </em>",
"      ,",
"      <em>",
"       PICALM",
"      </em>",
"      , and",
"      <em>",
"       BIN1",
"      </em>",
"      variants. In addition, a region containing the genes",
"      <em>",
"       EXOC3L2",
"      </em>",
"      ,",
"      <em>",
"       BLOC1S3",
"      </em>",
"      , and",
"      <em>",
"       MARK4",
"      </em>",
"      surpassed the genome-wide significance threshold [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Alzheimer&rsquo;s Disease Genetics Consortium (ADGC), which includes nearly all existing GWAS datasets in the United States totaling 12,000 cases and 11,000 controls also confirmed the effects of",
"      <em>",
"       CLU",
"      </em>",
"      ,",
"      <em>",
"       PICALM",
"      </em>",
"      ,",
"      <em>",
"       CR1",
"      </em>",
"      , and",
"      <em>",
"       BIN1",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/90\">",
"       90",
"      </a>",
"      ]. Genome-wide significant association signals were also seen at",
"      <em>",
"       EPHA1",
"      </em>",
"      , in a cluster of genes that includes",
"      <em>",
"       MS4A4A",
"      </em>",
"      and",
"      <em>",
"       MS4A6E",
"      </em>",
"      , in SNPs near",
"      <em>",
"       CD33",
"      </em>",
"      (which is on chromosome 19, 6 Mb from the",
"      <em>",
"       APOE",
"      </em>",
"      locus), and near",
"      <em>",
"       CD2AP",
"      </em>",
"      on chromosome 14. A companion meta-analysis replicated many of these findings and also identified one novel locus,",
"      <em>",
"       ABCA7",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even combined, the predictive value of these genes for LOAD remains quite modest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/88\">",
"     88",
"    </a>",
"    ]. As an example, the attributable risks for the first three validated AD genes were estimated to be 25.5 percent for",
"    <em>",
"     APOE",
"    </em>",
"    , 8.9 percent for",
"    <em>",
"     CLU",
"    </em>",
"    and 3.8 percent for",
"    <em>",
"     CR1",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/87\">",
"     87",
"    </a>",
"    ]. Although the population-attributable risk for",
"    <em>",
"     APOE",
"    </em>",
"    ,",
"    <em>",
"     CLU",
"    </em>",
"    ,",
"    <em>",
"     PICALM",
"    </em>",
"    , and",
"    <em>",
"     CR1",
"    </em>",
"    combined was later estimated to be as high as 56 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/92\">",
"     92",
"    </a>",
"    ], this estimate was likely inflated and driven primarily by",
"    <em>",
"     APOE",
"    </em>",
"    . Using a true population sample, a separate study reported a very modest increase in the predictive value of a model containing age, sex,",
"    <em>",
"     APOE",
"    </em>",
"    ,",
"    <em>",
"     PICALM",
"    </em>",
"    ,and",
"    <em>",
"     CLU",
"    </em>",
"    over one containing just age, sex, and",
"    <em>",
"     APOE",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are some data to suggest that rare variants in",
"    <em>",
"     APP",
"    </em>",
"    ,",
"    <em>",
"     PSEN1",
"    </em>",
"    and",
"    <em>",
"     PSEN2",
"    </em>",
"    may contribute to disease risk in LOAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/93\">",
"     93",
"    </a>",
"    ]. In addition, rare heterozygous variants in the gene that encodes triggering receptor expressed on myeloid cells 2 (",
"    <em>",
"     TREM2)",
"    </em>",
"    , a gene known to be associated with a rare autosomal recessive form of dementia, have been associated with increased risk of LOAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of these and other candidate genes in the pathogenesis of AD is an area of active investigation. While it is unlikely that these genes will be useful in diagnosis, they may offer mechanistic insights that will potentially lead to new therapies. (See",
"    <a class=\"local\" href=\"#H900049\">",
"     'Challenges'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H900049\">",
"    <span class=\"h1\">",
"     CHALLENGES",
"    </span>",
"   </p>",
"   <p>",
"    <strong>",
"     Limitations of linkage analyses",
"    </strong>",
"    &mdash; Linkage studies suffer from several important limitations, the sum of which largely explains why this technique has not been more effective in determining the specific genetic bases of late-onset Alzheimer disease (LOAD). First, the small number of markers used results in low resolution to identify linked regions and the responsible genes. These studies are also vulnerable to locus heterogeneity, which occurs when different families have different AD risk genes. Since linkage statistics basically sum the evidence for a disease gene in a given region over all families, the net evidence for linkage in a given region is often weak, despite the presence of a true risk gene. Many early linkage studies also suffered from insufficient sample size.",
"   </p>",
"   <p>",
"    <strong>",
"     Limitations of candidate gene studies",
"    </strong>",
"    &mdash; Of the very large number of AD loci implicated by candidate gene studies, very few have been replicated consistently. Possible explanations include false positive results, lack of adequate power to detect or replicate an association because of sample size, lack of informative markers within a gene, locus heterogeneity (different genes underlying the same AD phenotype), and clinical heterogeneity (multiple clinical subtypes associated with different sets of susceptibility genes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/92\">",
"     92",
"    </a>",
"    ]. Lack of consistency across studies may also be due to intralocus heterogeneity (ie, different risk mutations within the same gene).",
"   </p>",
"   <p>",
"    <strong>",
"     Limitations of genome-wide association studies",
"    </strong>",
"    &mdash; Although many of the limitations inherent to candidate gene studies have been overcome by GWAS, important limitations and challenges to remain. Overall, GWAS have not explained as much of the variance in AD as was originally expected, a challenge that is not unique to AD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/95\">",
"     95",
"    </a>",
"    ]. There are several hypotheses about why this might be the case across multiple common diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=see_link&amp;anchor=H7#H7\">",
"     \"Genetic association studies: Principles and applications\", section on 'Genome-wide association studies (GWAS)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=see_link&amp;anchor=H6#H6\">",
"     \"Genetic association studies: Principles and applications\", section on 'Missing heritability'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In AD, one possibility is that the majority of the heritability has already been explained by the net effect of the thousands of SNPs nominally associated with AD, but that these SNPs fail to meet the multiple test-corrected significance threshold. If true, sample sizes of hundreds of thousands or more subjects would be needed to separate the true from the false associations. Considering the very small effects these SNPs are predicted to have on AD risk, the disease-predictive value or therapeutic target potential gained would likely be minimal. Larger sample sizes do not result in larger effect sizes, however, and the small effect sizes associated with the vast majority of SNPs thus far identified may be the most important impediment to clinical relevance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with the candidate gene approach, many individual GWAS findings over the years have not been verified in independent samples. Several factors contribute to this inconsistency, including variable definitions of cases and controls, subject ascertainment, variability of SNP genotyping platforms and microarray chips, and sample size.",
"   </p>",
"   <p>",
"    <strong>",
"     Unexplained risk",
"    </strong>",
"    &mdash; A basic assumption regarding genetic determinants of a complex disease such as LOAD is that common variants in many genes will each lead to a small rise or fall in the risk of disease, and that the overall risk of disease is determined by the combination of multiple variants and environmental exposures. However, genetic studies to date have a mixed track record, and a substantial proportion of LOAD heritability remains unexplained.",
"   </p>",
"   <p>",
"    Aside from the limitations of candidate and genome-wide association studies discussed above, one possibility for this is termed the &ldquo;common disease-rare variant&rdquo; theory. This theory would posit that multiple, rare, family-specific mutations in common genes and biological pathways explain the remaining AD heritability. A large proportion of these rare variants are not detectable using the microarray chips used in GWAS. As the cost of next generation sequencing becomes increasingly affordable, large-scale projects are underway to identify these rare variants and test them for association with AD using gene based methods.",
"   </p>",
"   <p>",
"    More complex statistical models are also being tested and used in an attempt to explain the remaining AD heritability. As with most complex diseases and biological systems in general, AD pathogenesis involves multiple proteins in multiple inter and intra-cellular pathways with multiple levels of regulation and feedback loops. Pathway and gene set enrichment analyses combine multiple lines of evidence, such as SNP association, gene expression, animal models, and literature mining, to identify pathways and networks involved in disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. As an example, an analysis of 2344 AD cases and 7076 controls showed significant enrichment of AD-associated SNPs in genes in several pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/96\">",
"     96",
"    </a>",
"    ]. As expected, the &ldquo;Alzheimer disease&rdquo; pathway showed the greatest level of enrichment, but several other pathways were significant, including &ldquo;regulation of autophagy,&rdquo; &ldquo;natural killer cell mediated cytotoxicity,&rdquo; &ldquo;antigen processing and presentation,&rdquo; and &ldquo;RIG-I-like receptor signaling.&rdquo;",
"   </p>",
"   <p>",
"    <strong>",
"     Translation to therapy",
"    </strong>",
"    &mdash; Despite statistical evidence for association, most functional variants in the established AD risk genes have not yet been identified, and the precise roles of their encoded proteins in AD pathogenesis are poorly understood. To date, no therapeutic interventions have been developed to intervene in the genes and pathways identified through GWAS. Functional studies such as mouse knockout models are required to better understand functions in both the context of normal biology and the pathology of AD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H900056\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with early-onset Alzheimer disease (AD) and those with a family history of AD may inquire about genetic testing, which has become more accessible through clinical laboratories and direct-to-consumer testing. The utility and advisability of testing differs for early-onset versus late-onset disease, and given the evolving nature of the field, formal genetics consultation should be recommended for families who express an interest in testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4579949\">",
"    <span class=\"h2\">",
"     Early-onset Alzheimer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic tests are commercially available for each of the early-onset, autosomal dominant forms of AD. Testing can either be symptomatic (ie, an individual patient diagnosed with early-onset AD and a family history suggesting autosomal dominant inheritance) or predictive (ie, presymptomatic individuals with a known mutation in their family). Prenatal testing is also available when a disease-causing mutation has been identified. An overview of genetic testing and specifics of available genetics tests is available online at",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/\">",
"     GeneTests",
"    </a>",
"    . Since multiple mutations in",
"    <em>",
"     PSEN1",
"    </em>",
"    ,",
"    <em>",
"     PSEN2",
"    </em>",
"    , and",
"    <em>",
"     APP",
"    </em>",
"    can all cause AD, sequencing the entire coding regions of the genes is necessary to comprehensively assess risk; this is not covered by commercial testing.",
"   </p>",
"   <p>",
"    Testing for highly penetrant genetic mutations like",
"    <em>",
"     APP, PSEN1",
"    </em>",
"    and",
"    <em>",
"     PSEN2",
"    </em>",
"    carries important implications for family members. Genetic counseling of symptomatic patients should be performed in the presence of the individual&rsquo;s legal guardian or a family member to ensure adequate informed consent and an understanding of the purpose of testing, the possible results, and their implications for other family members [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/98\">",
"     98",
"    </a>",
"    ]. Studies have shown that relatively few family members of individuals with early-onset AD choose to be tested. Although those that are usually cope well with the results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/99\">",
"     99",
"    </a>",
"    ], depression has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/100\">",
"     100",
"    </a>",
"    ]. It is ultimately up to the relatives of early-onset AD patients whether to undergo genetic testing. Physicians and genetic counselors have the responsibility to inform them of the option and communicate the implications of having potentially inherited a dominant mutation with almost complete penetrance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4579956\">",
"    <span class=\"h2\">",
"     Late-onset Alzheimer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For late-onset Alzheimer disease (LOAD), the predictive value of the LOAD risk variants described above is extremely limited, with the lone exception of",
"    <em>",
"     APOE",
"    </em>",
"    &epsilon;4.",
"    <em>",
"     APOE",
"    </em>",
"    genotyping in presymptomatic individuals is controversial and has generally been discouraged because of the low sensitivity and specificity of testing, the lack of preventive options, and the apparent variability of risk conferred by",
"    <em>",
"     APOE",
"    </em>",
"    across genders and ethnicities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1026225\">",
"     'Strength of association'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When testing is performed, it appears that most individuals do not suffer undue psychological harm in the short term after results are revealed, but the long term impact has not been well studied. In a randomized study, 162 adults who had a parent with AD were randomized to having their &epsilon;4 status disclosed or not. Subjects who learned they were &epsilon;4-positive and were therefore at increased risk for AD showed no more anxiety, depression, or test-related distress than those who did not learn their genotype. Conversely, test-related distress was reduced among those who learned that they were APOE &epsilon;4&ndash;negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32089/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commercial DNA testing services have become more popular over the past several years and some companies include APOE genotyping in the available panel. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8777?source=see_link&amp;anchor=H2097388#H2097388\">",
"     \"Personalized medicine\", section on 'Direct-to-consumer testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1026643\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genetic contribution to Alzheimer disease (AD) risk remains poorly understood despite major advances in the 1990&rsquo;s in the identification of three genes that cause early-onset familial AD and one significant genetic risk factor for late-onset AD (LOAD). There have been three main strategies employed to identify genetic factors that predispose to the development of AD: linkage analysis, candidate gene studies, and genome-wide association studies. (See",
"      <a class=\"local\" href=\"#H1025787\">",
"       'Approaches to gene discovery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genetic basis for AD is best understood in the early-onset form, which accounts for less than one percent of cases and typically follows an autosomal dominant inheritance pattern. To date, pathogenic mutations in three genes have been identified as causative of early-onset Alzheimer disease: amyloid precursor protein (",
"      <em>",
"       APP",
"      </em>",
"      ), presenilin 1 (",
"      <em>",
"       PSEN1",
"      </em>",
"      ), and presenilin 2 (",
"      <em>",
"       PSEN2",
"      </em>",
"      ). (See",
"      <a class=\"local\" href=\"#H6562978\">",
"       'Early-onset Alzheimer Disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genetic basis of late-onset Alzheimer disease (LOAD) is more complex, with susceptibility conferred by a variety of more common but less penetrant genetic factors, likely interacting with environmental and epigenetic influences. To date, the only established genetic risk factor for late-onset disease is apoprotein E &epsilon;4 (",
"      <em>",
"       APOE",
"      </em>",
"      &epsilon;4). (See",
"      <a class=\"local\" href=\"#H2663413\">",
"       'Late-onset Alzheimer disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite decades of research, much of the heritability of AD remains unexplained. (See",
"      <a class=\"local\" href=\"#H900049\">",
"       'Challenges'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing is available for the known causative genes in early-onset AD but has not been widely adopted, likely in part because of the current lack of highly effective preventative or therapeutic strategies.",
"      <em>",
"       APOE",
"      </em>",
"      genotyping in presymptomatic individuals is generally discouraged but is becoming more accessible through direct-to-consumer testing. (See",
"      <a class=\"local\" href=\"#H900056\">",
"       'Genetic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/1\">",
"      Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer's disease locus on chromosome 1. Science 1995; 269:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/2\">",
"      St George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992; 2:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/3\">",
"      Schellenberg GD, Bird TD, Wijsman EM, et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 1992; 258:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/4\">",
"      Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987; 235:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/5\">",
"      Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/6\">",
"      Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/7\">",
"      Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/8\">",
"      Renbaum P, Levy-Lahad E. Monogenic determinants of familial Alzheimer's disease: presenilin-2 mutations. Cell Mol Life Sci 1998; 54:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/9\">",
"      Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995; 376:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/10\">",
"      Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/11\">",
"      Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999; 65:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/12\">",
"      Janssen JC, Beck JA, Campbell TA, et al. Early onset familial Alzheimer's disease: Mutation frequency in 31 families. Neurology 2003; 60:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/13\">",
"      Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/14\">",
"      Priller C, Bauer T, Mitteregger G, et al. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 2006; 26:7212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/15\">",
"      Eckman CB, Mehta ND, Crook R, et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 1997; 6:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/16\">",
"      Rostagno A, Holton JL, Lashley T, et al. Cerebral amyloidosis: amyloid subunits, mutants and phenotypes. Cell Mol Life Sci 2010; 67:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/17\">",
"      Sahlin C, Lord A, Magnusson K, et al. The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. J Neurochem 2007; 101:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/18\">",
"      Tsubuki S, Takaki Y, Saido TC. Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 2003; 361:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/19\">",
"      Tomiyama T, Nagata T, Shimada H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 2008; 63:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/20\">",
"      Di Fede G, Catania M, Morbin M, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009; 323:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/21\">",
"      Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006; 38:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/22\">",
"      Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006; 129:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/23\">",
"      Cabrejo L, Guyant-Mar&eacute;chal L, Laquerri&egrave;re A, et al. Phenotype associated with APP duplication in five families. Brain 2006; 129:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/24\">",
"      Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. J Neurochem 2005; 93:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/25\">",
"      Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010; 19:R4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/26\">",
"      Sherrington R, Froelich S, Sorbi S, et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum Mol Genet 1996; 5:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/27\">",
"      Finckh U, Alberici A, Antoniazzi M, et al. Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology 2000; 54:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/28\">",
"      Bird TD, Levy-Lahad E, Poorkaj P, et al. Wide range in age of onset for chromosome 1--related familial Alzheimer's disease. Ann Neurol 1996; 40:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/29\">",
"      Tedde A, Nacmias B, Ciantelli M, et al. Identification of new presenilin gene mutations in early-onset familial Alzheimer disease. Arch Neurol 2003; 60:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/30\">",
"      Wolozin B, Iwasaki K, Vito P, et al. Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 1996; 274:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/31\">",
"      Oyama F, Cairns NJ, Shimada H, et al. Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. J Neurochem 1994; 62:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/32\">",
"      Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/33\">",
"      Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995; 346:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/34\">",
"      Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/35\">",
"      Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995; 333:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/36\">",
"      Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med 1995; 1:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/37\">",
"      Graff-Radford NR, Green RC, Go RC, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol 2002; 59:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/38\">",
"      Chang JB, Wang PN, Chen WT, et al. ApoE epsilon4 allele is associated with incidental hallucinations and delusions in patients with AD. Neurology 2004; 63:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/39\">",
"      Chapman J, Wang N, Treves TA, et al. ACE, MTHFR, factor V Leiden, and APOE polymorphisms in patients with vascular and Alzheimer's dementia. Stroke 1998; 29:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/40\">",
"      Skoog I, Hesse C, Aevarsson O, et al. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998; 64:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/41\">",
"      Slooter AJ, Cruts M, Hofman A, et al. The impact of APOE on myocardial infarction, stroke, and dementia: the Rotterdam Study. Neurology 2004; 62:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/42\">",
"      Ballard CG, Morris CM, Rao H, et al. APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology 2004; 63:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/43\">",
"      Myers RH, Schaefer EJ, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: The Framingham study. Neurology 1996; 46:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/44\">",
"      Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Ann Hum Genet 1999; 63:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/45\">",
"      Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ 2004; 171:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/46\">",
"      Goldstein FC, Ashley AV, Gearing M, et al. Apolipoprotein E and age at onset of Alzheimer's disease in African American patients. Neurology 2001; 57:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/47\">",
"      Olarte L, Schupf N, Lee JH, et al. Apolipoprotein E epsilon4 and age at onset of sporadic and familial Alzheimer disease in Caribbean Hispanics. Arch Neurol 2006; 63:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/48\">",
"      Dal Forno G, Carson KA, Brookmeyer R, et al. APOE genotype and survival in men and women with Alzheimer's disease. Neurology 2002; 58:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/49\">",
"      Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005; 65:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/50\">",
"      Mori E, Lee K, Yasuda M, et al. Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 2002; 51:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/51\">",
"      Geroldi C, Laakso MP, DeCarli C, et al. Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 2000; 68:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/52\">",
"      Scarmeas N, Brandt J, Albert M, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002; 58:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/53\">",
"      Tiraboschi P, Hansen LA, Masliah E, et al. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology 2004; 62:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/54\">",
"      Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009; 72:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/55\">",
"      Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology 2004; 63:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/56\">",
"      Blair CK, Folsom AR, Knopman DS, et al. APOE genotype and cognitive decline in a middle-aged cohort. Neurology 2005; 64:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/57\">",
"      Packard CJ, Westendorp RG, Stott DJ, et al. Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc 2007; 55:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/58\">",
"      Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006; 63:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/59\">",
"      Persson J, Lind J, Larsson A, et al. Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology 2006; 66:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/60\">",
"      Lind J, Persson J, Ingvar M, et al. Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers. Brain 2006; 129:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/61\">",
"      Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/62\">",
"      Wishart HA, Saykin AJ, McAllister TW, et al. Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology 2006; 67:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/63\">",
"      Conrad C, Vianna C, Freeman M, Davies P. A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease. Proc Natl Acad Sci U S A 2002; 99:7751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/64\">",
"      Seripa D, Matera MG, D'Andrea RP, et al. Alzheimer disease risk associated with APOE4 is modified by STH gene polymorphism. Neurology 2004; 62:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/65\">",
"      Thambisetty M, An Y, Nalls M, et al. Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 2013; 73:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/66\">",
"      Caselli RJ, Dueck AC, Locke DE, et al. Cerebrovascular risk factors and preclinical memory decline in healthy APOE &epsilon;4 homozygotes. Neurology 2011; 76:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/67\">",
"      Evans DA, Bennett DA, Wilson RS, et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch Neurol 2003; 60:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/68\">",
"      Tang MX, Maestre G, Tsai WY, et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet 1996; 58:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/69\">",
"      Sahota A, Yang M, Gao S, et al. Apolipoprotein E-associated risk for Alzheimer's disease in the African-American population is genotype dependent. Ann Neurol 1997; 42:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/70\">",
"      Shadlen MF. Effects of age and ethnicity on the link between APOE epsilon4 and Alzheimer disease. JAMA 1998; 279:581; author reply 581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/71\">",
"      Murrell JR, Price B, Lane KA, et al. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch Neurol 2006; 63:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/72\">",
"      Gureje O, Ogunniyi A, Baiyewu O, et al. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol 2006; 59:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/73\">",
"      Horsburgh K, McCarron MO, White F, Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/74\">",
"      Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981; 256:9077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/75\">",
"      Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A 1982; 79:4696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/76\">",
"      Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/77\">",
"      Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92:4725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/78\">",
"      Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 1995; 92:12260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/79\">",
"      Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988; 240:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/80\">",
"      Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 1994; 17:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/81\">",
"      Peskind ER, Wilkinson CW, Petrie EC, et al. Increased CSF cortisol in AD is a function of APOE genotype. Neurology 2001; 56:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/82\">",
"      Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/83\">",
"      Mooser V, Helbecque N, Miklossy J, et al. Interactions between apolipoprotein E and apolipoprotein(a) in patients with late-onset Alzheimer disease. Ann Intern Med 2000; 132:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/84\">",
"      Kivipelto M, Helkala EL, Laakso MP, et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/85\">",
"      Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998; 338:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/86\">",
"      Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/87\">",
"      Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/88\">",
"      Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/89\">",
"      Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/90\">",
"      Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/91\">",
"      Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/92\">",
"      Ertekin-Taner N. Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther 2010; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/93\">",
"      Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012; 7:e31039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/94\">",
"      Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/95\">",
"      Klein C, Lohmann K, Ziegler A. The Promise and Limitations of Genome-wide Association Studies. JAMA 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/96\">",
"      Lambert JC, Grenier-Boley B, Chouraki V, et al. Implication of the immune system in Alzheimer's disease: evidence from genome-wide pathway analysis. J Alzheimers Dis 2010; 20:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/97\">",
"      Hong MG, Alexeyenko A, Lambert JC, et al. Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease. J Hum Genet 2010; 55:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/98\">",
"      Goldman JS, Hahn SE, Catania JW, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med 2011; 13:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/99\">",
"      Steinbart EJ, Smith CO, Poorkaj P, Bird TD. Impact of DNA testing for early-onset familial Alzheimer disease and frontotemporal dementia. Arch Neurol 2001; 58:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/100\">",
"      Quaid KA, Murrell JR, Hake AM, Farlow MR. Presymptomatic genetic testing with an APP mutation. J Genet Couns 2000; :327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32089/abstract/101\">",
"      Green RC, Roberts JS, Cupples LA, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009; 361:245.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16195 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-8AB89F2CF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32089=[""].join("\n");
var outline_f31_21_32089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1026643\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6562986\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1025787\">",
"      APPROACHES TO GENE DISCOVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1027823\">",
"      Linkage analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1025837\">",
"      Candidate gene studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1025931\">",
"      Genome-wide association studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6562978\">",
"      EARLY-ONSET ALZHEIMER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2663392\">",
"      Amyloid precursor protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2663399\">",
"      Presenilin 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2663406\">",
"      Presenilin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H912645\">",
"      Trisomy 21",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2663413\">",
"      LATE-ONSET ALZHEIMER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H899448\">",
"      Apolipoprotein E",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1026217\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1026225\">",
"      - Strength of association",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1026240\">",
"      - Proposed mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1026606\">",
"      - Diagnostic utility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H899456\">",
"      Other candidate genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H900049\">",
"      CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H900056\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4579949\">",
"      Early-onset Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4579956\">",
"      Late-onset Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1026643\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26138?source=related_link\">",
"      Mild cognitive impairment: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/36/8777?source=related_link\">",
"      Personalized medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/22/36202?source=related_link\">",
"      Risk factors for dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_21_32090="Medical management of claudication";
var content_f31_21_32090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of claudication",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     Denis L Clement, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/21/32090/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/21/32090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with compromise of blood flow to the extremities most commonly present with pain of a muscle group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/1\">",
"     1",
"    </a>",
"    ]. Claudication (derived from the Latin word for limp) is defined as a reproducible discomfort of a defined group of muscles that is induced by exercise and relieved with rest. The symptoms result from an imbalance between the supply and demand for blood flow due to peripheral artery disease (PAD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a diagnosis of PAD is established, typically using noninvasive studies, the clinician must design a management strategy that may include one or more of the following components: risk factor modification of hypertension, diabetes, obesity and hyperlipidemia; pharmacotherapy and exercise to increase walking tolerance; and interventional therapy (eg, balloon angioplasty, stenting, atherectomy, endarterectomy, and bypass). The medical management of claudication will be reviewed here. The indications for percutaneous intervention and surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTOR MODIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal risk factors for the development of peripheral artery disease (PAD) are cigarette smoking, diabetes mellitus, hypertension, and hyperlipidemia. One study of 6450 subjects estimated that 69 percent of the incidence of PAD is attributable to these risk factors, with cigarette smoking being the most important factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast,",
"    <strong>",
"     moderate",
"    </strong>",
"    alcohol consumption reduces the risk of PAD and claudication, as it does the risk of coronary disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30201?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of shared risk factors, patients with peripheral artery disease are also at high risk for coronary and cardiovascular events and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel [ATP] III) considered PAD to be a coronary heart disease risk equivalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall approach to primary and secondary prevention of cardiovascular disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=see_link\">",
"     \"Overview of primary prevention of coronary heart disease and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cessation of cigarette smoking reduces the progression of peripheral artery disease (PAD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. As an example, one study of 343 patients with claudication compared the clinical outcomes among those who quit smoking (39 patients) with those who continued to smoke (304 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/10\">",
"     10",
"    </a>",
"    ]. Rest pain, a sign of severe ischemia, developed in 16 percent of patients who continued to smoke but not at all in patients who stopped smoking.",
"   </p>",
"   <p>",
"    It is not clear whether smoking cessation reduces the severity of claudication symptoms. In a meta-analysis that looked at pain-free and total walking distance outcomes, smoking cessation was found useful, but only in nonrandomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the following recommendations regarding smoking cessation made in the 2011 update to the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of patients with PAD, and the 2007 TASC II consensus document on the management of PAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12-14\">",
"     12-14",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients who are smokers or former smokers should be asked about the status of tobacco use at every visit",
"     </li>",
"     <li>",
"      All patients should be strongly advised to stop smoking by their physicians",
"     </li>",
"     <li>",
"      All patients should be offered pharmacotherapy, behavior modification, referral to a smoking cessation program, and counseling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled trials have directly evaluated the effects of antidiabetic therapy upon the natural history of peripheral artery disease (PAD). Aggressive control of blood sugar in both type 1 and type 2 diabetes reduces the risk of microvascular complications (eg, nephropathy, retinopathy, and neuropathy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, in the Diabetes Control and Complications Trial of patients with type 1 diabetes, intensive insulin therapy had no effect upon the risk of PAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/17\">",
"     17",
"    </a>",
"    ]. The results were similar in the United Kingdom Prospective Diabetes Study of patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link&amp;anchor=H18#H18\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We largely agree with the 2007 TASC II consensus document on the management of PAD, which recommends aggressive control of blood glucose levels with an A1C goal of &lt;7.0 percent and as close to 6.0 percent as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12,18,19\">",
"     12,18,19",
"    </a>",
"    ]. Less stringent goals may be appropriate for some patients (eg, older patients and those with comorbid conditions). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a major risk factor for PAD. However, there are no data evaluating whether antihypertensive therapy alters the progression of claudication. Nevertheless, hypertension should be controlled in these patients to reduce morbidity from cardiovascular and cerebrovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12\">",
"     12",
"    </a>",
"    ]. Blood pressure management in patients with cardiovascular disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been concern involving the use of beta blockers in the treatment of hypertension among patients with claudication, but there appears to be",
"    <strong>",
"     no",
"    </strong>",
"    adverse effect of beta-1 selective blockers on claudication symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. As a result, these drugs are not contraindicated in patients with PAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of cholesterol-lowering trials in patients with hyperlipidemia and coronary artery disease or PAD have evaluated the effects on PAD. Initial studies, performed before the availability of statins, showed regression or less progression of femoral atherosclerosis with lipid-lowering therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], and a lower incidence of claudication and limb-threatening ischemia in patients with hyperlipidemia who were treated with surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/26\">",
"     26",
"    </a>",
"    ]. A 2000 Cochrane meta-analysis of mostly older trials that specifically evaluated patients with lower limb atherosclerosis concluded that lipid-lowering therapy reduced disease progression (as measured by angiography) and helped alleviate symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent studies confirmed these benefits in patients treated with statin therapy. Regression of femoral atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/28\">",
"     28",
"    </a>",
"    ], a lower rate of new or worsening claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/29\">",
"     29",
"    </a>",
"    ], and improvements in walking distance and pain-free walking time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/30-32\">",
"     30-32",
"    </a>",
"    ] have all been described. The range of findings can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A post-hoc analysis of the Scandinavian",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      Survival Study (4S), which included 4444 patients with angina or previous myocardial infarction and a baseline plasma total cholesterol between 212 and 309",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.5 and 8.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      found that treatment with 20 to 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of simvastatin reduced the incidence of new or worsening claudication by 38 percent (2.3 versus 3.6 percent with placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized, double-blind trial included 354 patients with claudication attributable to PAD who were assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (10 or 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/31\">",
"       31",
"      </a>",
"      ]. At 12 months, there was a significant improvement in pain-free walking time with high-dose atorvastatin (63 versus 38 percent with placebo [81 versus 39 seconds]) and in community-based physical activity with both doses of atorvastatin. There was no change in ankle-brachial index (ABI).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Statin therapy may also reduce the incidence of cardiovascular events in patients with PAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. This was suggested by a study of 515 patients (mean ABI 0.51) who underwent percutaneous intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/33\">",
"     33",
"    </a>",
"    ]. At a median follow-up of 21 months, 65 patients died. Patients treated with a statin had a significant reduction in all-cause mortality (adjusted hazard ratio 0.52) and in death or nonfatal myocardial infarction (adjusted hazard ratio 0.48). A similar reduction in all-cause mortality in patients with PAD who are treated with statins (hazard ratio 0.46) was noted in a larger prospective observational cohort study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence for benefit and the appropriate goals for cholesterol lowering in patients with all forms of cardiovascular disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the following recommendations regarding lipid control made in the 2007 TASC II consensus document on the management of PAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients with PAD should have their LDL-cholesterol lowered to &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      In patients with PAD and atherosclerosis in other circulatory beds, it is reasonable to lower the LDL-cholesterol to &lt;70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factor summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for PAD are similar to those for other forms of atherosclerotic vascular disease, and PAD is associated with an increased risk of coronary, cerebrovascular, and renovascular disease. As a result, PAD is considered a coronary heart disease equivalent, thereby elevating it to the highest risk category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    practice guidelines on PAD, updated in 2011, and the 2007 TASC II consensus document on the management of PAD recommended smoking cessation, lipid lowering with statin therapy, and treatment of diabetes and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. These secondary prevention recommendations are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEDICAL VERSUS INTERVENTIONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for claudication may involve medical, percutaneous,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical approaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/36\">",
"     36",
"    </a>",
"    ]. Most patients with claudication are treated initially with medical therapy, which, in addition to risk modification (as described above), includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exercise therapy",
"     </li>",
"     <li>",
"      Pharmacologic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indications for revascularization and the choice between percutaneous intervention and surgery are discussed in detail separately. Two important criteria for revascularization are severe disability that limits the patient's ability to work or to perform other activities that are important to the patient, and failure (or predicted failure) to respond to exercise and pharmacologic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUPERVISED EXERCISE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated the benefit of a supervised exercise rehabilitation program in reducing the symptoms of claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/37-42\">",
"     37-42",
"    </a>",
"    ]. Community-based supervised therapy may be as effective as a hospital-based approach for improving walking distance, but is associated with a high dropout rate. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/43\">",
"     43",
"    </a>",
"    ]. Psychological support is important for any successful exercise program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of randomized trials performed between 1966 and 1997 found that exercise therapy produced a significant increase in maximum walking time (mean difference 6.5 minutes); the benefit was greater than that seen with angioplasty at six months (mean difference 3.3 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/37\">",
"     37",
"    </a>",
"    ]. A subsequent trial found similar improvements in patients with aortoiliac occlusive disease. In this study, 111 patients with claudication were randomly assigned to supervised exercise therapy, stent revascularization, or optimal medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/42\">",
"     42",
"    </a>",
"    ]. The peak change in walking time at six-months follow-up was greatest for supervised exercise, intermediate for stent revascularization, and least with optimal medical therapy (mean change versus baseline, 5.8, 3.7, and 1.2 minutes, respectively). The study protocol allowed femoropopliteal endovascular revascularization to treat any additional focal lesions, but this was not performed for any study participant.",
"   </p>",
"   <p>",
"    <br/>",
"    A later systematic review identified 11 trials performed between 1990 and 2011 comparing supervised exercise therapy with intervention and found that a combination of percutaneous transluminal angioplasty (PTA) and exercise (supervised exercise therapy or exercise advice) may produce greater changes in walking distance compared with exercise or PTA alone, but this did not uniformly translate to a quality of life improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several mechanisms by which exercise training may improve claudication, although the available data are insufficient to make conclusions regarding their relative importance of each [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improved endothelial function increases endothelial-dependent dilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=see_link\">",
"       \"Endothelial dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduced local inflammation (induced by muscle ischemia) by decreasing free radicals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased exercise pain tolerance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Induction of vascular angiogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improved muscle metabolism by favorable effects on muscle",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      metabolism and other pathways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced red cell aggregation and in blood viscosity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue is whether walking distance in asymptomatic patients with PAD improves with exercise rehabilitation. This issue was addressed in a study of 156 patients (ABI &le;0.95; 81 percent asymptomatic), who were randomly assigned to one of three intervention groups: supervised treadmill exercise, lower extremity resistance training, or no such therapy (control) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/52\">",
"     52",
"    </a>",
"    ]. At six months, participants in the treadmill exercise group had significant increases in maximal treadmill walking time, walking impairment distance score, and short form-36 physical functioning scores compared with those in the control group.",
"   </p>",
"   <p>",
"    These trials used lower extremity exercise (eg, treadmill or walking). The effect of upper limb exercise was assessed in a subsequent trial in which 104 patients with stable peripheral artery disease were randomly assigned to twice weekly aerobic exercise training with upper limb or lower limb exercise or a nonexercise training control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/48\">",
"     48",
"    </a>",
"    ]. At six months, upper and lower limb exercise were associated with similar increases in claudication distance (51 and 57 percent), maximal walking distance (29 and 31 percent), and peak oxygen consumption.",
"   </p>",
"   <p>",
"    Although less well studied, exercise may also improve survival. This was addressed in an observational study of 225 men and women with PAD in whom physical activity was measured with a vertical accelerometer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients were followed for a mean duration of 57 months at which time 75 patients (33 percent) had died. Individuals in the highest quartile of accelerometer-measured activity had a significantly lower risk of death (hazard ratio 0.29, 95% CI 0.10-0.83) compared with those in lowest quartile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Exercise prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be referred to a claudication exercise rehabilitation program, but unfortunately, supervised exercise training programs may not be covered by the patient&rsquo;s medical insurance.",
"   </p>",
"   <p>",
"    Supervised programs consist of a series of sessions lasting 45 to 60 minutes per session, using a motorized treadmill or a track to permit each patient to achieve symptom-limited claudication. The initial session usually includes 35 minutes of intermittent walking; walking is then increased by five minutes each session until 50 minutes of intermittent walking can be accomplished, surrounded by warm-up and cool-down sessions of 5 to 10 minutes each.",
"   </p>",
"   <p>",
"    Ideally, the patient attends at least three sessions per week, with a program length greater than three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"     14",
"    </a>",
"    ]. Each session is supervised on a one-to-one basis by an exercise physiologist, physical therapist, or nurse. The supervising provider monitors the individual patient's claudication threshold and other cardiovascular limitations for adjustment of workload. During this supervised rehabilitation program, the development of new arrhythmias, symptoms that might suggest angina, or the continued inability of the patient to progress to an adequate level of exercise may require physician review and examination of the patient.",
"   </p>",
"   <p>",
"    Most patients who eventually respond to a supervised exercise protocol can expect improvement within two months but the benefits of exercise diminish when exercise training stops. Motivated patients achieve the best results.",
"   </p>",
"   <p>",
"    Despite the evidence of benefit, issues remain concerning the optimal regimen for exercise rehabilitation. In a trial cited above, for example, the improvement in claudication distance with an exercise regimen was similar with lower limb and upper limb exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, the optimal intensity of exercise is uncertain.",
"   </p>",
"   <p>",
"    In an initial randomized trial addressing the issue of intensity of exercise, a regimen of low-intensity exercise for six months produced similar improvements in claudication distance and health-related quality of life as high-intensity exercise (40 versus 80 percent of maximal exercise capacity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another issue is the value of unsupervised exercise, which may be particularly important when access to supervised programs is limited by transportation, availability, cost or insurance coverage. In an observational study of 417 patients with peripheral artery disease, those patients who reported self-directed walking for exercise &ge;3 times per week walked more city blocks per week (as measured by an accelerometer) and had a significantly lower annual decline in six minute walking distance than those who walked one to two times per week or did not exercise (-48 versus -57 and -79 feet per year) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/55\">",
"     55",
"    </a>",
"    ]. A Similar benefit was noted in patients who walked &ge;90 minutes per week compared with a shorter duration of exercise. Benefit from exercise was also seen in the subset of patients who were asymptomatic as manifested by smaller annual declines in six-minute walking performance.",
"   </p>",
"   <p>",
"    The relative efficacy of supervised and unsupervised exercise in patients with claudication has been compared in eight randomized trials, which were included in a 2006 meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/56\">",
"     56",
"    </a>",
"    ]. Walking was the dominant form of exercise training in both groups. The primary end point was maximal treadmill walking distance before and after a three-month period of training. Supervised exercise led to a significantly greater improvement of approximately 150 meters (30 to 35 percent difference in improvement). However, quality-of-life measures (secondary end points) were not significantly different between the two groups. A more recent trial comparing supervised exercise therapy to a home-based regimen was consistent with the results of the metaanalysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast, another trial randomly assigned patients with claudication to usual activity, a home-based exercise therapy quantified with step activity monitor, or supervised exercise therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/58\">",
"     58",
"    </a>",
"    ]. As with other studies, significant increases in the time to onset of claudication and peak walking time were found for exercise compared with controls, but there were no significant differences between the supervised and home-based regimens.",
"   </p>",
"   <p>",
"    Active feedback has also been incorporated into supervised training regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. &nbsp;A multicenter trial in a community setting with physical therapists staffing outpatient vascular surgery clinics randomly assigned 304 patients to supervised exercise training with accelerometer feedback, supervised training without feedback, or unsupervised walking at home following instruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/59\">",
"     59",
"    </a>",
"    ]. Supervised exercise training significantly improved walking distance (360 meters with feedback, 310 meters without feedback) compared with unsupervised walking at home (110 meters) (",
"    <a class=\"graphic graphic_figure graphicRef57368 \" href=\"mobipreview.htm?23/59/24511\">",
"     figure 1",
"    </a>",
"    ). In this study, improvements in quality of life measures corresponded to improvements in walking distance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy of claudication is aimed at symptomatic relief or slowing the progression of the natural disease. A number of drugs have been evaluated but, as will be seen, the evidence of benefit is convincing only for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    and antiplatelet agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/13,14,61\">",
"     13,14,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of drug therapy aimed at risk factor modification are discussed above. The discussion below focuses on improvement of claudication symptoms. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Risk factor modification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451547835\">",
"    <span class=\"h2\">",
"     Cilostazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     Cilostazol",
"    </a>",
"    is a phosphodiesterase inhibitor that suppresses platelet aggregation and is a direct arterial vasodilator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/62\">",
"     62",
"    </a>",
"    ]. Benefits to therapy are noted as early as four weeks after the initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/63\">",
"     63",
"    </a>",
"    ]. Based upon the evidence of benefit discussed below, a therapeutic trial (three to six months) of cilostazol (100 mg orally twice daily) is recommended (in the absence of heart failure) to improve symptoms and increase walking distance in patients with lifestyle-limiting claudication, particularly if antiplatelet agents and exercise rehabilitation are ineffective and revascularization cannot be offered or is declined by the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12,14,61,64\">",
"     12,14,61,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     Cilostazol",
"    </a>",
"    should be taken one-half hour before or two hours after eating, because high-fat meals markedly increase absorption. Several drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , as well as grapefruit juice, can increase serum concentrations of cilostazol if taken concurrently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/65\">",
"     65",
"    </a>",
"    ]. Cilostazol may be taken safely with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    without an additional increase in bleeding time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/66\">",
"     66",
"    </a>",
"    ]. Side effects for cilostazol noted in clinical studies included headache, loose and soft stools, diarrhea, dizziness and palpitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/63,67-69\">",
"     63,67-69",
"    </a>",
"    ]. Nonsustained ventricular tachycardia has been reported. Because other oral phosphodiesterase inhibitors used for inotropic therapy have caused increased mortality in patients with advanced heart failure, cilostazol is contraindicated in heart failure of any severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link&amp;anchor=H3#H3\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\", section on 'Phosphodiesterase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    has been demonstrated in two meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In one of these, 2702 patients with stable moderate to severe claudication were randomly assigned to cilostazol or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/70\">",
"     70",
"    </a>",
"    ]. Patients treated with 100 mg cilostazol twice daily for 12 to 24 weeks experienced significantly greater increases in maximal and pain-free walking distances (50 and 67 percent, versus 22 and 40 percent, respectively) compared with the placebo group.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     Cilostazol",
"    </a>",
"    appears to be more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Pentoxifylline'",
"    </a>",
"    below). This was illustrated in a trial of 698 patients randomly assigned to cilostazol (100 mg twice daily), pentoxifylline (400 mg three times daily), or placebo for 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/72\">",
"     72",
"    </a>",
"    ]. The increase in mean maximal walking distance over baseline with pentoxifylline and placebo was the same (30 and 34 percent, respectively), but the increase with cilostazol was significantly greater (54 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antiplatelet agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preponderance of data on the use of currently available antiplatelet agents indicate that no improvement or only a modest improvement in claudication can be expected and that a significant benefit may not be seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone. Thus, the main indication for antiplatelet therapy is for secondary prevention of coronary disease and stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      &ndash; The Antithrombotic Trialists' Collaboration overview analyzed the results of randomized trials of antiplatelet therapy among more than 135,000 high-risk patients with prior evidence of cardiovascular disease, including myocardial infarction, stroke, transient ischemic attacks, unstable angina, stable angina, revascularization surgery, angioplasty, atrial fibrillation, valvular disease, and PAD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/73\">",
"       73",
"      </a>",
"      ]. Moderate dose aspirin (75 to 325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was most commonly prescribed.",
"      <br/>",
"      <br/>",
"      Among 26 trials of patients with claudication, 12 with peripheral grafting, and 4 with peripheral angioplasty, antiplatelet therapy was associated with a significant reduction in the risk of nonfatal myocardial infarction, nonfatal stroke, or vascular death (5.8 versus 7.1 percent, odds reduction 23 percent) (",
"      <a class=\"graphic graphic_table graphicRef56243 \" href=\"mobipreview.htm?42/34/43564\">",
"       table 1",
"      </a>",
"      ). The magnitude of benefit was similar in the three groups.",
"      <br/>",
"      <br/>",
"      However, the data on aspirin alone do not suggest a statistically significant benefit in the broad PAD population, including asymptomatic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/74\">",
"       74",
"      </a>",
"      ]. The overall benefit of antiplatelet therapies in the Antithrombotic Trialists' Collaboration data was driven by data from trials using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/73,75\">",
"       73,75",
"      </a>",
"      ].The Physicians Health Study, a primary prevention study, found that 325 mg of aspirin every other day decreased the need for peripheral artery surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/76\">",
"       76",
"      </a>",
"      ]. However, no difference was noted between the aspirin and placebo groups in the development of claudication.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      &ndash; The combination of aspirin and dipyridamole was found to increase the pain-free walking distance and resting limb blood-flow in a study of 54 patients with claudication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/77\">",
"       77",
"      </a>",
"      ]. Another study in 296 patients with claudication found an improved coagulation profile and",
"      <span class=\"nowrap\">",
"       ankle/brachial",
"      </span>",
"      index with therapy, but did not report if walking distance improved with combined therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       Ticlopidine",
"      </a>",
"      &ndash; Ticlopidine, an inhibitor of platelet aggregation, appears to modestly increase walking distance in patients with claudication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/79\">",
"       79",
"      </a>",
"      ]. However, the drug is associated with a substantial risk of leukopenia and thrombocytopenia, requiring close hematologic monitoring for at least three months. Other potential side effects include bleeding, dyspepsia, diarrhea, nausea, anorexia, rash, purpura, and dizziness. The usual dose of ticlopidine is 250 mg twice daily, with food.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      &ndash; Clopidogrel is similar to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      but considered a safer drug. The CAPRIE trial found that clopidogrel (75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      had a modest, although significant advantage over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      for the prevention of stroke, myocardial infarction (MI), and PAD in 19,185 patients with a recent stroke, MI, or PAD (annual rate of 5.3 versus 5.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/80\">",
"       80",
"      </a>",
"      ]. However, an estimated 2 to 14 percent of patients may be poor metabolizers of clopidogrel due to reduced functioning of the liver enzyme that converts clopidogrel to its active form [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/81\">",
"       81",
"      </a>",
"      ]. Resistance to antiplatelet therapy is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link&amp;anchor=H2#H2\">",
"       \"Nonresponse and resistance to clopidogrel\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Antiplatelet summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of randomized studies with antiplatelet agents found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    had the best evidence of efficacy (ie, improvement in walking distance, reduction in occlusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    improvement in mortality) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, as noted above, the CAPRIE trial found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was more effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in preventing vascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is generally considered the antiplatelet drug of choice because of the high incidence of comorbid coronary disease, the benefits of aspirin in preventing myocardial infarction, and lower cost.",
"   </p>",
"   <p>",
"    We agree with the following recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12-14,64\">",
"     12-14,64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiplatelet therapy is indicated to reduce the risk of MI, stroke, and vascular death in individuals with symptomatic atherosclerotic lower extremity PAD, including those with claudication.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is the antiplatelet agent of choice;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      may be used if aspirin cannot be tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pentoxifylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     Pentoxifylline",
"    </a>",
"    is a rheologic modifier approved for use in the United States for the symptomatic relief of claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Its putative mechanisms of action include increased deformability of red blood cells and blood viscosity, decreases in fibrinogen concentration, and reduced platelet adhesiveness.",
"   </p>",
"   <p>",
"    Studies investigating the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    have yielded conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. A meta-analysis found that pentoxifylline improved walking distance by 29 meters compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/87\">",
"     87",
"    </a>",
"    ]. The improvement was approximately 50 percent in the placebo group, while pentoxifylline provided an additional 30 percent. A later systematic review identified 23 trials, 17 of which compared pentoxifylline with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/88\">",
"     88",
"    </a>",
"    ]. The difference in percentage improvement in total walking distance for pentoxifylline over placebo ranged from 1.2 to 156 percent, and for pain-free walking distance the difference ranged from -34 to 74 percent. The authors noted considerable heterogeneity between the included studies, and a pooled analysis was not performed.",
"   </p>",
"   <p>",
"    These data indicate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    is of questionable benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"     14",
"    </a>",
"    ]. Any improvements in walking distances associated with pentoxifylline are generally substantially less than that achieved with a supervised exercise program (123 percent increase in peak walking time in one study) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/39\">",
"     39",
"    </a>",
"    ], or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008 Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) recommended against the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/61\">",
"     61",
"    </a>",
"    ], while the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that pentoxifylline (400 mg three times per day) may be considered a second-line drug to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    to improve walking distance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"     14",
"    </a>",
"    ]. The 2007 TASC II consensus document on the management of PAD makes no recommendation on the use of pentoxifylline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other rheologic modifiers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodilution therapy for reducing the plasma viscosity involves removing blood and replacing it with a colloidal solution of hydroxyethyl starch (HES) or a low-molecular-weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    (LMWD) one to two times weekly for several weeks. This approach has resulted in some improvement in pain-free walking distance in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/89,90\">",
"     89,90",
"    </a>",
"    ], but the relatively small benefit achieved does not warrant routine use of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Naftidrofuryl",
"    </span>",
"    &nbsp;&mdash;&nbsp;Naftidrofuryl is a 5-hydroxytryptamine-2-receptor antagonist that is currently available only in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/91-93\">",
"     91-93",
"    </a>",
"    ]. The mechanisms of action of this drug are unclear but it is thought to promote glucose uptake and increase adenosine triphosphate levels. A metaanalysis of four trials showed an increase in the time to initial pain development on treadmill walking and significant increases in pain-free walking distance over a three to six month period compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/11\">",
"     11",
"    </a>",
"    ]. A separate analysis of newer studies found a significant increased mean gain in walking distance of 159 feet (48.44 m) (95% CI 118-200 feet [35.84-60.95m]), compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007 TASC II consensus document on the management of PAD concluded that naftidrofuryl (600 mg daily orally) can be considered for the treatment of claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ginkgo biloba",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ginkgo biloba has been studied in patients with claudication with modest success. The mechanism by which ginkgo may work in this disorder is unclear, but may involve a number of activities including an antioxidant effect, inhibition of vascular injury, and antithrombotic effects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11720?source=see_link\">",
"     \"Clinical use of ginkgo biloba\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a metaanalysis of 11 trials, patients who received ginkgo biloba extract had no significant differences in initial claudication distance. A trend toward improvement in the absolute claudication distance was seen for ginkgo biloba with the treadmill distances standardized between the protocols by converting to kilocalories, a mean difference of 3.57 that corresponded to about 200 feet (64 meters), but the difference was not significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/95\">",
"     95",
"    </a>",
"    ]. There were also a number of flaws with the included studies, including lack of clarity about randomization. The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that benefit has",
"    <strong>",
"     not",
"    </strong>",
"    been established for ginkgo biloba for the treatment of claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, there remain concerns about recommending herbal products in general since the administration of these remedies is not regulated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Regulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Standardization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ineffective therapies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      &ndash; Warfarin has not been shown to improve cardiovascular outcomes in patients with PAD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estrogen replacement therapy &ndash; The effect of estrogen replacement therapy (ERT) on the incidence of PAD is unclear. In a population-based study of 2196 postmenopausal women, ERT for one year or more was associated with a 52 percent decreased risk of peripheral artery disease (defined as an",
"      <span class=\"nowrap\">",
"       ankle/arm",
"      </span>",
"      systolic blood pressure index lower than 0.9) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/78\">",
"       78",
"      </a>",
"      ]. In contrast, the Heart and",
"      <span class=\"nowrap\">",
"       Estrogen/Progestin",
"      </span>",
"      Replacement Study (HERS) of 2763 postmenopausal women with coronary heart disease found that hormone replacement therapy with estrogen and progesterone did not significantly reduce the incidence of peripheral arterial events (relative hazard 0.87 compared with placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/79\">",
"       79",
"      </a>",
"      ]. Based upon the latter report, ERT does not appear to have a role in the management of peripheral vascular disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chelation therapy &ndash; The use of repeated intravenous infusion of EDTA or \"chelation therapy\" has been advocated by some researchers in the treatment of claudication. A double-blind, randomized, controlled trial was conducted to evaluate the effectiveness of chelation therapy in patients with claudication. The main outcome measure was walking distances and",
"      <span class=\"nowrap\">",
"       ankle/brachial",
"      </span>",
"      pulse indices. No significant difference between the chelation therapy group and the control group was observed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/96\">",
"       96",
"      </a>",
"      ].The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines concluded that chelation therapy was not beneficial and may be harmful in the treatment of claudication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin E supplementation &ndash; Vitamin E has been evaluated in the treatment of coronary heart disease because of its antioxidant properties. Several small trials have evaluated its efficacy in the treatment of claudication; there was no clear evidence of benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/97\">",
"       97",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines concluded that vitamin E was not recommended for the treatment of claudication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Investigational agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following agents are being investigated in patients with claudication. Their clinical use is not yet recommended.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Angiotensin inhibition &ndash; Angiotensin inhibition might provide symptomatic benefit in patients with claudication. This was evaluated in a small randomized trial in which 40 older patients with claudication were assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/37/24152?source=see_link\">",
"       ramipril",
"      </a>",
"      (10 mg once daily) or placebo for 24 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/98\">",
"       98",
"      </a>",
"      ]. After adjustment for baseline values, ramipril therapy was associated with a significant 227 second increase in pain-free walking time and a significant 451 second increase in maximum walking time; no changes were noted in the placebo group. The generalizability of this initial observation is unclear since there were strict inclusion criteria, including superficial femoral artery stenosis or occlusion. Patients with diabetes, hypertension, or coronary heart disease and those with a history of ACE inhibitor therapy were excluded. Further studies are required before the use of ACE inhibitors for claudication can be recommended.",
"     </li>",
"     <li>",
"      Antichlamydophila therapy &ndash; It has been proposed that chronic Chlamydophila (formerly Chlamydia) pneumoniae infection may promote the development of atherosclerosis and clinical trials of antichlamydophila therapy have been performed in a variety of clinical settings. This hypothesis was tested in a randomized, placebo-controlled trial that investigated the efficacy of an antichlamydophila antibiotic, roxithromycin (300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 30 days), to prevent progression of peripheral artery disease (PAD) in 40 men who were seropositive for C. pneumoniae, and had established PAD and at least one carotid plaque detectable by ultrasonography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/99\">",
"       99",
"      </a>",
"      ]. During 2.7 year follow-up, patients treated with roxithromycin experienced significantly fewer invasive revascularizations (5 versus 29 interventions) compared with placebo, and had significantly less frequent limitation to 200 m walking distance (20 versus 65 percent). These observations need to be confirmed in a larger trial of patients with PAD, particularly in view of the lack of benefit of antichlamydophila therapy in major trials of patients with coronary disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25160?source=see_link\">",
"       \"Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Propionyl-L-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      &ndash; The mechanism of action of propionyl-L-carnitine in patients with claudication is thought to be via increased energy metabolism in ischemic muscle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/100,101\">",
"       100,101",
"      </a>",
"      ]. A double-blind placebo-controlled study of 245 patients with claudication found that active therapy resulted in a modest increase in maximal walking distance (73 versus 46 percent with placebo) and time to initial pain on treadmill walking [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/100,101\">",
"       100,101",
"      </a>",
"      ]. In a follow-up report from this trial, propionyl-L-carnitine, but not placebo, resulted in an improvement in quality of life, emotional status, and physical function among patients with more severely limited walking capacity (&lt;250 meters) at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/102\">",
"       102",
"      </a>",
"      ]. In contrast, patients with mild functional impairment (walking distance &gt;250 meters) had no response to the drug [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/103\">",
"       103",
"      </a>",
"      ]. Other studies have also found that propionyl-L-carnitine improves exercise performance and functional status in patients with claudication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/104\">",
"       104",
"      </a>",
"      ]. The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines concluded that benefit is not well established for propionyl-L-carnitine for the treatment of claudication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/8/41091?source=see_link\">",
"       Defibrotide",
"      </a>",
"      &ndash; Defibrotide is a polydeoxyribonucleotide that stimulates fibrinolysis via increased release of tissue plasminogen activator and prostacyclin and reduced release of plasminogen activator inhibitor from endothelial cells. Defibrotide also decreases beta thromboglobulin and may therefore act by inhibiting platelet aggregation. The results from a placebo-controlled trial study reported an increased maximal treadmill walking distance over a six-month period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostaglandins &ndash; Prostaglandin E1 (PGE1) is a vasodilator and an inhibitor of platelet aggregation. However, it is rapidly inactivated in the lungs, and must be given intra-arterially or intravenously using large doses. PGE1 is experimental and has not been approved for clinical use. In a study of 80 patients with claudication, intravenous administration of a prostaglandin E1 prodrug produced a dose-related improvement in walking distance and quality of life at four and eight weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/106\">",
"       106",
"      </a>",
"      ]. A Cochrane review of five studies comparing PGE1 (eg, alprostadil,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      ) with placebo found that significant increases in walking distances were attained with PGE1, which persisted even after termination of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/107\">",
"       107",
"      </a>",
"      ]. Further randomized trials were recommended to confirm these results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beraprost is an orally-active prostaglandin I2 (prostacyclin) analog that has antiplatelet and vasodilating properties. Its efficacy was evaluated in the BERCI-2 trial of 549 patients with a pain-free walking distance of 50 to 300 meters that changed by &lt;25 percent during a four week placebo run-in phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/108\">",
"     108",
"    </a>",
"    ]. After six months, patients had a &gt;50 percent increase in walking distance on a treadmill and on one or more earlier treadmill tests with beraprost (40 mcg three times daily) compared with placebo (44 versus 33 percent). The pain-free walking distances increased by 82 and 53 percent, respectively, and the maximum walking distances increased by 60 and 35 percent, respectively. The incidence of critical cardiovascular events (cardiac death, myocardial infarction, coronary revascularization, stroke, transient ischemic attack, or critical or subcritical leg ischemia requiring medical or surgical intervention) was lower but not statistically significantly so (4.8 versus 8.9 for placebo).",
"   </p>",
"   <p>",
"    Different results were found in another study of 897 patients, which had the same study design as BERCI-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/109\">",
"     109",
"    </a>",
"    ]. Patients were treated with beraprost (40 mcg three times daily) or placebo after a three week placebo run-in period. At six months, there was no difference between beraprost and placebo in the improvement of mean walking distance or pain-free walking distance. There was no significant improvement in quality of life for either group. The reasons for the difference in outcomes between BERCI-2 and this study may include a lower incidence of hypertension, diabetes, and lipid disorders and a higher baseline",
"    <span class=\"nowrap\">",
"     ankle/brachial",
"    </span>",
"    index in the BERCI-2 study population.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that oral vasodilation prostaglandins were not effective for the treatment of claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"     14",
"    </a>",
"    ] and the 2008 American College of Chest Physicians Evidence-Based Clinical Practice Guidelines on antithrombotic and thrombolytic therapy (8th Edition) recommended against the use of prostaglandins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NM-702 &ndash; NM-702 is an investigational phosphodiesterase inhibitor that has been shown in phase I and II studies to be well tolerated and to improve treadmill performance. It has the additional potentially beneficial property of inhibiting human platelet thromboxane A2 synthetase. In a study of safety and efficacy, 386 individuals with clinically stable claudication were randomly assigned to placebo or to NM-702 (4 mg or 8 mg twice daily for 24 weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/110\">",
"       110",
"      </a>",
"      ]. Statistically significant improvements in treadmill claudication onset and peak walking times were noted. The drug was well tolerated and no unanticipated safety concerns were found.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mesoglycan &ndash; Mesoglycan, a sulfated polysaccharide compound containing the thrombin inhibitors heparan and dermatan sulfate, is available in some European countries. One randomized trial of 242 patients treated for 23 weeks found that a clinical response, defined as &ge;50 percent increase over baseline in absolute walking distance, was more frequently achieved with Mesoglycan (50 versus 26 percent with placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glutathione &mdash; Glutathione is an antioxidant that improved pain-free walking distance in a randomized, double-blind, placebo-controlled study of 40 patients with claudication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/112\">",
"       112",
"      </a>",
"      ]. However, glutathione was administered intravenously twice daily, an obvious disadvantage compared with oral therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic angiogenesis &ndash; Animal studies have suggested that angiogenic growth factors can stimulate the development of collateral arteries, an approach known as therapeutic angiogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/113\">",
"       113",
"      </a>",
"      ]. The safety and efficacy of therapeutic angiogenesis in humans is under investigation with variable results in patients with peripheral artery disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/114-117\">",
"       114-117",
"      </a>",
"      ]. It is also being evaluated in other disorders such as refractory angina and limb-threatening ischemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/4/6216?source=see_link\">",
"       \"Therapeutic angiogenesis for management of refractory angina\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=see_link&amp;anchor=H30#H30\">",
"       \"Treatment of chronic lower extremity critical limb ischemia\", section on 'Stimulation of angiogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, the TRAFFIC trial evaluated the role of recombinant fibroblast growth factor-2 (rFGF-2) in 190 patients with claudication due to infrainguinal peripheral artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/116\">",
"     116",
"    </a>",
"    ]. Patients were randomly assigned to bilateral lower limb arterial infusions of placebo, single dose rFGF-2, or repeat dose rFGF-2 on days 1 and 30. At 90 days, a single infusion of rFGF-2 was associated with a significant increase in peak walking time compared with placebo (increase of 1.77 versus 0.6 minutes compared with baseline); there was no additional benefit from a second infusion. This was a phase II study that was not powered to detect functional improvements in activities of daily living or quality of life.",
"   </p>",
"   <p>",
"    However, the RAVE trial found no benefit from intramuscular injection of an adenoviral vector transmitting the vascular endothelial growth factor (VEGF) gene in 105 patients with claudication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/117\">",
"     117",
"    </a>",
"    ]. Changes from baseline in peak walking time, claudication onset time,",
"    <span class=\"nowrap\">",
"     ankle/brachial",
"    </span>",
"    index and quality of life were similar at 12 and 26 weeks with two doses of VEGF compared with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909618361\">",
"    <span class=\"h1\">",
"     COMPRESSION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent mechanical (nonpneumatic) calf compression has been used to treat claudication. A trial that randomly assigned 30 patients with stable claudication to active intermittent compression versus medical therapy alone found significantly increased claudication distance (66 percent), absolute claudication distance (42 percent) and postexercise (but not resting) ankle-brachial index (42 percent) at one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/21/32090/abstract/118\">",
"     118",
"    </a>",
"    ]. Treatment effects were maintained or further improved after three months and after cessation of therapy at three months, postexercise ankle-brachial index did not decrease significantly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/49/34578?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The therapy of patients with claudication involves risk factor modification, an exercise program, antiplatelet therapy, and possibly medical therapy for improvement in symptoms. The following recommendations are generally consistent with the American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association",
"      <span class=\"nowrap\">",
"       (ACC/AHA)",
"      </span>",
"      guidelines for peripheral artery disease (PAD), the TASC II consensus document on the management of PAD, the 2012 American College of Chest Physicians (ACCP) guideline on antithrombotic therapy for peripheral artery disease, and the 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines on secondary prevention. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk factors for PAD are similar to those for other forms of atherosclerotic vascular disease, and PAD is associated with an increased risk of coronary, cerebrovascular, and renovascular disease. As a result, PAD is considered as a coronary heart disease risk equivalent. Because of this risk, secondary prevention modalities are recommended to the goals set in current national guidelines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factor modification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A supervised exercise program is recommended as part of the initial treatment regimen. It should be performed for a minimum of 30 to 45 minutes at least three times per week for a minimum of 12 weeks. During each session, an exercise level that is of sufficient intensity to elicit claudication should be achieved. The value of an unsupervised exercise program is less well studied, but is generally recommended for patients who cannot participate in supervised exercise programs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Supervised exercise therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiplatelet agents (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 162",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      are warranted in patients with claudication to reduce the risk of myocardial infarction, stroke, and cardiovascular mortality. For secondary prevention, we do not use dual antiplatelet therapy in the absence of other indications (eg, drug-eluting stent, prosthetic distal lower extremity bypass). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antiplatelet agents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among the medical therapies that have been evaluated for the treatment of claudication, convincing evidence of benefit is available only for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"       Cilostazol",
"      </a>",
"      &ndash; A therapeutic trial of cilostazol (100 mg orally twice daily) is recommended (in the absence of heart failure) to improve symptoms and increase walking distance in patients with lifestyle-limiting claudication, particularly if antiplatelet agents and exercise therapy have been ineffective and revascularization cannot be offered or is declined by the patient. Cilostazol should be taken one-half-hour before or two hours after eating, because high-fat meals markedly increase absorption. Several drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      , as well as grapefruit juice, can increase serum concentrations of cilostazol if taken concurrently. Cilostazol may be taken safely with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      without an additional increase in bleeding time. Because other oral phosphodiesterase inhibitors used for inotropic therapy have caused increased mortality in patients with advanced heart failure, cilostazol is contraindicated in heart failure of any severity. (See",
"      <a class=\"local\" href=\"#H451547835\">",
"       'Cilostazol'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link&amp;anchor=H3#H3\">",
"       \"Inotropic agents in heart failure due to systolic dysfunction\", section on 'Phosphodiesterase inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/28/13765?source=see_link\">",
"       Pentoxifylline",
"      </a>",
"      &ndash; The available data indicate that the benefit of pentoxifylline is marginal. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Pentoxifylline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other &ndash; The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines concluded that benefit is not established for ginkgo biloba, L-arginine, and propionyl-L-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      in patients with claudication, and that oral vasodilator prostaglandins are not effective, vitamin E is not recommended, and chelation therapy may be harmful.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/1\">",
"      European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/2\">",
"      Meijer WT, Grobbee DE, Hunink MG, et al. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 2000; 160:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/3\">",
"      Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/4\">",
"      Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/5\">",
"      O'Hare AM, Katz R, Shlipak MG, et al. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006; 113:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/6\">",
"      Hussein AA, Uno K, Wolski K, et al. Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol 2011; 57:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/7\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/8\">",
"      Ameli FM, Stein M, Provan JL, Prosser R. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 1989; 3:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/9\">",
"      Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982; 69 Suppl:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/10\">",
"      Jonason T, Bergstr&ouml;m R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987; 221:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/11\">",
"      Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/12\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/13\">",
"      2011 WRITING GROUP MEMBERS, 2005 WRITING COMMITTEE MEMBERS, ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/14\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/15\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/16\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/17\">",
"      Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/18\">",
"      Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/19\">",
"      Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/20\">",
"      Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/21\">",
"      Solomon SA, Ramsay LE, Yeo WW, et al. beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991; 303:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/22\">",
"      Thadani U, Whitsett TL. Beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med 1991; 151:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/23\">",
"      Barndt R Jr, Blankenhorn DH, Crawford DW, Brooks SH. Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Intern Med 1977; 86:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/24\">",
"      Duffield RG, Lewis B, Miller NE, et al. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet 1983; 2:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/25\">",
"      Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991; 83:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/26\">",
"      Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery 1996; 120:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/27\">",
"      Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 2000; :CD000123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/28\">",
"      de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/29\">",
"      Pedersen TR, Kjekshus J, Py&ouml;r&auml;l&auml; K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/30\">",
"      Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/31\">",
"      Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/32\">",
"      Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/33\">",
"      Schillinger M, Exner M, Mlekusch W, et al. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004; 25:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/34\">",
"      Feringa HH, van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 47:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/35\">",
"      Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/36\">",
"      Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/37\">",
"      Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000; :CD000990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/38\">",
"      Wolosker N, Nakano L, Rosoky RA, Puech-Leao P. Evaluation of walking capacity over time in 500 patients with intermittent claudication who underwent clinical treatment. Arch Intern Med 2003; 163:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/39\">",
"      Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990; 81:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/40\">",
"      Gardner AW, Skinner JS, Bryant CX, Smith LK. Stair climbing elicits a lower cardiovascular demand than walking in claudication patients. J Cardiopulm Rehabil 1995; 15:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/41\">",
"      Frans FA, Bipat S, Reekers JA, et al. Systematic review of exercise training or percutaneous transluminal angioplasty for intermittent claudication. Br J Surg 2012; 99:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/42\">",
"      Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012; 125:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/43\">",
"      Kruidenier LM, Nicola&iuml; SP, Hendriks EJ, et al. Supervised exercise therapy for intermittent claudication in daily practice. J Vasc Surg 2009; 49:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/44\">",
"      Cunningham MA, Swanson V, O'Carroll RE, et al. Randomized clinical trial of a brief psychological intervention to increase walking in patients with intermittent claudication. Br J Surg 2012; 99:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/45\">",
"      Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med 2002; 347:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/46\">",
"      Brendle DC, Joseph LJ, Corretti MC, et al. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol 2001; 87:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/47\">",
"      Tisi PV, Shearman CP. The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking? Eur J Vasc Endovasc Surg 1998; 15:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/48\">",
"      Zwierska I, Walker RD, Choksy SA, et al. Upper- vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: a randomized controlled trial. J Vasc Surg 2005; 42:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/49\">",
"      Gustafsson T, Kraus WE. Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. Front Biosci 2001; 6:D75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/50\">",
"      Hiatt WR, Regensteiner JG, Wolfel EE, et al. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol 1996; 81:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/51\">",
"      Ernst EE, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation 1987; 76:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/52\">",
"      McDermott MM, Ades P, Guralnik JM, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 2009; 301:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/53\">",
"      Garg PK, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006; 114:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/54\">",
"      Gardner AW, Montgomery PS, Flinn WR, Katzel LI. The effect of exercise intensity on the response to exercise rehabilitation in patients with intermittent claudication. J Vasc Surg 2005; 42:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/55\">",
"      McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006; 144:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/56\">",
"      Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2006; :CD005263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/57\">",
"      van Asselt AD, Nicola&iuml; SP, Joore MA, et al. Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice. Eur J Vasc Endovasc Surg 2011; 41:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/58\">",
"      Gardner AW, Parker DE, Montgomery PS, et al. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation 2011; 123:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/59\">",
"      Nicola&iuml; SP, Teijink JA, Prins MH, Exercise Therapy in Peripheral Arterial Disease Study Group. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg 2010; 52:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/60\">",
"      Nicola&iuml; SP, Hendriks EJ, Prins MH, et al. Optimizing supervised exercise therapy for patients with intermittent claudication. J Vasc Surg 2010; 52:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/61\">",
"      Sobel M, Verhaeghe R, American College of Chest Physicians, American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:815S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/62\">",
"      Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/63\">",
"      Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/64\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/65\">",
"      Drugs for intermittent claudication. Med Lett Drugs Ther 2004; 46:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/66\">",
"      Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/67\">",
"      Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/68\">",
"      Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/69\">",
"      Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/70\">",
"      Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/71\">",
"      Pande RL, Hiatt WR, Zhang P, et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010; 15:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/72\">",
"      Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/73\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/74\">",
"      Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/75\">",
"      Hiatt WR, Krantz MJ. Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc Med 2006; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/76\">",
"      Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/77\">",
"      Libretti A, Catalano M. Treatment of claudication with dipyridamole and aspirin. Int J Clin Pharmacol Res 1986; 6:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/78\">",
"      Westendorp IC, in't Veld BA, Grobbee DE, et al. Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. Arch Intern Med 2000; 160:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/79\">",
"      Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 2000; 102:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/80\">",
"      CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/81\">",
"      Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, Writing Committee Members, et al. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA \"boxed warning\": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010; 122:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/82\">",
"      Girolami B, Bernardi E, Prins MH, et al. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 1999; 81:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/83\">",
"      Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 1984; 35:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/84\">",
"      Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/85\">",
"      Reich T, Cutler BC, Lee BY, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology 1984; 35:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/86\">",
"      R&ouml;ssner M, M&uuml;ller R. On the assessment of the efficacy of pentoxifylline (Trental). J Med 1987; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/87\">",
"      Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996; 155:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/88\">",
"      Salhiyyah K, Senanayake E, Abdel-Hadi M, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2012; 1:CD005262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/89\">",
"      Ernst E, Kollar L, Matrai A. [Hemodilution in peripheral arterial occlusive disease. Placebo controlled randomized double-blind study with hydroxyethyl starch or dextran]. Acta Med Austriaca 1991; 18 Suppl 1:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/90\">",
"      Kiesewetter H, Blume J, Jung F, et al. Haemodilution with medium molecular weight hydroxyethyl starch in patients with peripheral arterial occlusive disease stage IIb. J Intern Med 1990; 227:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/91\">",
"      Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994; 23 Suppl 3:S48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/92\">",
"      Moody AP, al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994; 23 Suppl 3:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/93\">",
"      Jung F, Kiesewetter H, Mrowietz C, et al. Hemorrheological, micro- and macrocirculatory effects of naftidrofuryl in an acute study: a randomized, placebo-controlled, double-blind individual comparison. Int J Clin Pharmacol Ther Toxicol 1987; 25:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/94\">",
"      De Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2008; :CD001368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/95\">",
"      Nicola&iuml; SP, Kruidenier LM, Bendermacher BL, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2009; :CD006888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/96\">",
"      van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994; 90:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/97\">",
"      Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000; :CD000987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/98\">",
"      Ahimastos AA, Lawler A, Reid CM, et al. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med 2006; 144:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/99\">",
"      Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation 2002; 105:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/100\">",
"      Brevetti G, Perna S, Sabb&aacute; C, et al. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995; 26:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/101\">",
"      Corsi C, Pollastri M, Marrapodi E, et al. L-propionylcarnitine effect on postexercise and postischemic hyperemia in patients affected by peripheral vascular disease. Angiology 1995; 46:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/102\">",
"      Brevetti G, Perna S, Sabba C, et al. Effect of propionyl-L-carnitine on quality of life in intermittent claudication. Am J Cardiol 1997; 79:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/103\">",
"      Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/104\">",
"      Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001; 110:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/105\">",
"      Avellone G, Mandal&agrave; V, Pinto A, et al. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs. Haemostasis 1986; 16 Suppl 1:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/106\">",
"      Belch JJ, Bell PR, Creissen D, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/107\">",
"      Reiter M, Bucek RA, St&uuml;mpflen A, Minar E. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2004; :CD000986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/108\">",
"      Li&egrave;vre M, Morand S, Besse B, et al. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/109\">",
"      Mohler ER 3rd, Hiatt WR, Olin JW, et al. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003; 41:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/110\">",
"      Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006; 48:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/111\">",
"      Nenci GG, Gresele P, Ferrari G, et al. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study. Thromb Haemost 2001; 86:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/112\">",
"      Arosio E, De Marchi S, Zannoni M, et al. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2002; 77:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/113\">",
"      Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/114\">",
"      Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/115\">",
"      Lazarous DF, Unger EF, Epstein SE, et al. Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol 2000; 36:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/116\">",
"      Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/117\">",
"      Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/21/32090/abstract/118\">",
"      de Haro J, Acin F, Florez A, et al. A prospective randomized controlled study with intermittent mechanical compression of the calf in patients with claudication. J Vasc Surg 2010; 51:857.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8210 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-92133E1D40-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32090=[""].join("\n");
var outline_f31_21_32090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTOR MODIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factor summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEDICAL VERSUS INTERVENTIONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUPERVISED EXERCISE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H451547835\">",
"      Cilostazol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antiplatelet agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Antiplatelet summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pentoxifylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other rheologic modifiers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Naftidrofuryl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ineffective therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Investigational agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H909618361\">",
"      COMPRESSION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8210|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/59/24511\" title=\"figure 1\">",
"      Benefit of supervised exercise therapy in claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8210|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/34/43564\" title=\"table 1\">",
"      Effect of antiplatelet therapy on vascular events",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25160?source=related_link\">",
"      Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/28/11720?source=related_link\">",
"      Clinical use of ginkgo biloba",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44376?source=related_link\">",
"      Indications for surgery in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/49/34578?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/4/6216?source=related_link\">",
"      Therapeutic angiogenesis for management of refractory angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_21_32091="Virulence factors K pneum";
var content_f31_21_32091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major virulence factors in pathogenicity of Klebsiella pneumoniae",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Virulence factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main components",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major function(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capsule (77 K serotypes)",
"       </td>",
"       <td>",
"        K1 or K2 capsular polysaccharide",
"       </td>",
"       <td>",
"        Antiphagocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypermucoviscosity phenotype",
"       </td>",
"       <td>",
"        Extracapsular polysaccharide",
"       </td>",
"       <td>",
"        Serum resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Lipopolysaccharide (O-antigen 9 serotypes: O1, O2, O2ac, O3, O4, O5, O7, O8, and O12)",
"       </td>",
"       <td>",
"        Lipopolysaccharide",
"       </td>",
"       <td>",
"        Endotoxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        O side chain",
"       </td>",
"       <td>",
"        Serum resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Siderophores",
"       </td>",
"       <td>",
"        Enterobactin, aerobactin, aerobactin receptor, kfu iron uptake system",
"       </td>",
"       <td>",
"        Enhanced growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Pili (fimbriae)",
"       </td>",
"       <td>",
"        Adhesin",
"       </td>",
"       <td>",
"        Attachment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 1 pili (FimH adhesion)",
"       </td>",
"       <td>",
"        Mannose-sensitive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 3 pili (MrkD adhesion)",
"       </td>",
"       <td>",
"        Mannose-resistant",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32091=[""].join("\n");
var outline_f31_21_32091=null;
var title_f31_21_32092="Gas properties at altitude";
var content_f31_21_32092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypobaric conditions at increasing altitude",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Altitude, ft",
"       </td>",
"       <td class=\"subtitle1\">",
"        Barometric pressure, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Atmospheric PO2, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tracheal PO2, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gas density*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gas volume**",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"(sea level)",
"       </td>",
"       <td>",
"        760",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2,000",
"       </td>",
"       <td>",
"        707",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4,000",
"       </td>",
"       <td>",
"        656",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5,000",
"       </td>",
"       <td>",
"        632",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        0.8",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8,000",
"       </td>",
"       <td>",
"        564",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        523",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15,000",
"       </td>",
"       <td>",
"        428",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30,000",
"       </td>",
"       <td>",
"        226",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40,000",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Fall in ambient pressure and PO2 at increasing altitude during air travel in commercial airliners. Pressurization of the cabin limits the reduction in cabin pressure, thereby limiting the reduction in inspired PO2.",
"    <div class=\"footnotes\">",
"     * Ratio of density at altitude to density at sea level.",
"     <br>",
"      &bull; Ratio of volume occupied by a fixed amount of gas at altitude to the volume occupied at sea level.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Gary, H, J Respir Dis 1990; 11:484.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32092=[""].join("\n");
var outline_f31_21_32092=null;
var title_f31_21_32093="Hepatocellular jaundice";
var content_f31_21_32093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of hepatocellular jaundice",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neoplasms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatocellular carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholangio carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metastases (bronchogenic, GI-tract, breast, GU-tract)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemangioendothelioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatoblastoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic/hereditary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wilson's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alpha-1-antitrypsin deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemochromatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Porphyrias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital hepatic fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibropolycystic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Systemic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute ischemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Severe heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricuspid insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Constrictive pericarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Budd-Chiari syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Venoocclusive disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Telangiectasias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyloidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Secondary biliary cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptogenic cirrhosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatitis viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Herpes viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Hemorrhagic\" viruses: yellow fever, Ebola, Marburg, Lassa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Adenoviruses, enteroviruses, etc",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tuberculosis, leptospirosis, syphilis, pyogenic abscess, brucella, rickettsia, tropheryma whippelii, rochalimea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Parasitic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Helminths: ascaris, fasciola, clonorchis, schistosomiasis, echinococcosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Protozoa: amebiasis, plasmodia, babesiosis, toxoplasmosis, leishmaniasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Candida, blastomyces, coccidioides, histoplasma, cryptococcus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Toxic/immunologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Medications (allergic, idiosyncratic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chlorinated hydrocarbons (carbon tetrachloride, chloroform)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amanita phalloides toxin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aflatoxin B1",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin A",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyrrolizidine alkaloids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phosphorous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Autoimmune Hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary biliary cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary sclerosing cholangitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Overlap syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Autoimmune cholangiopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonalcoholic steatohepatitis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32093=[""].join("\n");
var outline_f31_21_32093=null;
var title_f31_21_32094="Role of VEGF in OHSS";
var content_f31_21_32094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82113&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Role of VEGF in OHSS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 388px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VEGF: Vascular endothelial growth factor; hCG: human chorionic gonadotropin.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32094=[""].join("\n");
var outline_f31_21_32094=null;
var title_f31_21_32095="Anencephaly";
var content_f31_21_32095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Most of the cranium is absent, exposing residual neural tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Marvin A Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_21_32095=[""].join("\n");
var outline_f31_21_32095=null;
